WHO Drug Information, Vol. 28, No. 1, 2014                                                Recommended INN: List 71



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 71
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–109) and Recommended (1–70) International Nonproprietary Names can be found in Cumulative List
No. 15, 2013 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 71
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–109) et recommandées (1–70) dans
la Liste récapitulative No. 15, 2013 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 71
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–109) y Recomendadas (1–70) se encuentran
reunidas en Cumulative List No. 15, 2013 (disponible sólo en CD-ROM).


                                                                                                                  71
Recommended INN: List 71                                               WHO Drug Information, Vol. 28, No. 1, 2014




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abaloparatidum
 abaloparatide                             synthetic human parathyroid hormone (37-70) analogue:
                                             2.29
                                           C -methyl[22-L-glutamic acid(F>E),23-L-leucine(F>L),25-L-glutamic
                                           acid(H>E),26-L-lysine(H>K),28-L-leucine(I>L),30-L-lysine(E>K),
                                           31-L-leucine(I>L)]human parathyroid hormone-related protein-(1-34)-
                                           proteinamide

 abaloparatide                             analogue de l'hormone parathyroïdienne humaine (37-70)
                                           synthétique:
                                            2.29
                                           C -méthyl[22-L-acide glutamique(F>E),23-L-leucine(F>L),
                                           25-L-acide glutamique(H>E),26-L-lysine(H>K),28-L-leucine(I>L),
                                           30-L-lysine(E>K),31-L-leucine(I>L)]protéine apparentée à l'hormone
                                           parathyroïdienne humaine-(1-34)-protéinamide

 abaloparatida                             análogo sintético de la hormona paratiroidea humana (37-70):
                                             2.29
                                           C -metil[22-L-ácido glutámico(F>E),23-L-leucina(F>L),25-L-ácido
                                           glutámico(H>E),26-L-lisina(H>K),28-L-leucina(I>L),
                                           30-L-lisina(E>K),31-L-leucina(I>L)]proteína relacionada con la
                                           hormona paratiroidea humana-(1-34)-proteinamida

                                           C174H300N56O49

                                            Sequence / Séquence / Secuencia
                                            AVSEHQLLHD KGKSIQDLRR RELLEKLLXK LHTA                      34

                                           Modified residues / Résidus modifiés / Restos modificados
                                               X           H3C CH3                      A         H CH3
                                               29                                      34               NH2
                                           2-methylAla H2N          CO2H            Ala-NH2 H2N
                                                                                                   O

 abecomotidum
 abecomotide                               human insulin-like growth factor 2 mRNA-binding protein 3 (IMP-3,
                                           hKOC)-(508-513)-peptide (part of the KH4 domain):
                                           L-lysyl-L-threonyl-L-valyl-L-asparaginyl-L-α-glutamyl-L-leucyl-
                                           L-glutaminyl-L-asparaginyl-L-leucine

 abécomotide                               protéine 3, se liant à l'ARN messager, du facteur 2 de croissance
                                           humain analogue de l'insuline (IMP-3, hKOC)-(508-513)-peptide
                                           (partie du domaine KH4):
                                           L-lysyl-L-thréonyl-L-valyl-L-asparaginyl-L-α-glutamyl-L-leucyl-
                                           L-glutaminyl-L-asparaginyl-L-leucine

 abecomotida                               proteína 3, que se une al ARN mensajero del factor 2 de crecimiento
                                           humano análogo de la insulina (IMP-3, hKOC)-(508-513)-péptido
                                           (parte del dominio KH4) :
                                           L-lisil-L-treonil-L-valil-L-asparaginil-L-α-glutamil-L-leucil-L-glutaminil-
                                           L-asparaginil-L-leucina

                                           C45H79N13O16

                                           Sequence / Séquence / Secuencia
                                           KTVNELQNL 9

72
WHO Drug Information, Vol. 28, No. 1, 2014                                                            Recommended INN: List 71




 abituzumabum #
 abituzumab                                  immunoglobulin G2-kappa, anti-[Homo sapiens ITGAV (integrin
                                             alphaV, CD51)], humanized monoclonal antibody;
                                             gamma2 heavy chain (1-447) with IGHG1 hinge region [humanized
                                             VH (Homo sapiens IGHV1-46*01 (77.30%) -(IGHD)-IGHJ6*01)
                                             [8.8.11] (1-118) -Homo sapiens IGHG (IGHG2*03 CH1 (119-216),
                                             IGHG1 hinge C5>S (221) (217-231), IGHG2*03 CH2 F84.3>A (296),
                                             N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-
                                             447)], (132-214')-disulfide with kappa light chain (1'-214') [humanized
                                             V-KAPPA (Homo sapiens IGKV1-33*01 (86.30%) -IGKJ2*01) [6.3.9]
                                             (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimer (227-227":230-
                                             230")-bisdisulfide

 abituzumab                                  immunoglobuline G2-kappa, anti-[Homo sapiens ITGAV (intégrine
                                             alphaV, CD51)], anticorps monoclonal humanisé;
                                             chaîne lourde gamma2 (1-447) avec une région charnière IGHG1
                                             [VH humanisé (Homo sapiens IGHV1-46*01 (77.30%) -(IGHD)-
                                             IGHJ6*01) [8.8.11] (1-118) -Homo sapiens IGHG (IGHG2*03 CH1
                                             (119-216), IGHG1 charnière C5>S (221) (217-231), IGHG2*03 CH2
                                             F84.3>A (296), N84.4>Q (297) (232-340), CH3 (341-445), CHS
                                             (446-447)) (119-447)], (132-214')-disulfure avec la chaîne légère
                                             kappa (1'-214') [V-KAPPA humanisé (Homo sapiens IGKV1-33*01
                                             (86.30%) -IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-
                                             214')]; dimère (227-227":230-230")-bisdisulfure

 abituzumab                                  inmunoglobulina G2-kappa, anti-[ ITGAV (integrina alfaV, CD51) de
                                             Homo sapiens], anticuerpo monoclonal humanizado; cadena pesada
                                             gamma2 (1-447) con una región bisagra GHG1 [VH humanizada
                                             (Homo sapiens IGHV1-46*01 (77.30%) -(IGHD)-IGHJ6*01) [8.8.11]
                                             (1-118) -Homo sapiens IGHG (IGHG2*03 CH1 (119-216), IGHG1
                                             bisagra C5>S (221) (217-231), IGHG2*03 CH2 F84.3>A (296),
                                             N84.4>Q (297) (232-340), CH3 (341-445), CHS (446-447)) (119-
                                             447)], (132-214')-disulfuro con la cadena ligera kappa (1'-214')
                                             [V-KAPPA humanizada (Homo sapiens IGKV1-33*01 (86.30%) -
                                             IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                             dímero (227-227":230-230")-bisdisulfuro


                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQQSGGE LAKPGASVKV SCKASGYTFS                  SFWMHWVRQA       PGQGLEWIGY       50
                                             INPRSGYTEY NEIFRDKATM TTDTSTSTAY                  MELSSLRSED       TAVYYCASFL       100
                                             GRGAMDYWGQ GTTVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSNFGTQTYT       200
                                             CNVDHKPSNT KVDKTVEPKS SDKTHTCPPC                  PAPPVAGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSHED PEVQFNWYVD                  GVEVHNAKTK       PREEQAQSTF       300
                                             RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA                  PIEKTISKTK       GQPREPQVYT       350
                                             LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPMLDS       400
                                             DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQDIS                  NYLAWYQQKP       GKAPKLLIYY 50
                                             TSKIHSGVPS RFSGSGSGTD YTFTISSLQP                  EDIATYYCQQ       GNTFPYTFGQ 100
                                             GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                             DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                             LSSPVTKSFN RGEC                                                               214

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96         145-201       261-321 367-425
                                                                   22''-96'' 145''-201'' 261''-321'' 367''-425''
                                             Intra-L (C23-C104) 23'-88' 134'-194'
                                                                  23'''-88''' 134'''-194'''
                                             Inter-H-L (CH1 10-CL 126) 132-214' 132''-214'''
                                             Inter-H-H (h 11, h 14) 227-227'' 230-230''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             None (owing to amino acid change: H CH2 N84.4>Q (297)), aucun (dû au changement
                                             d'acide aminé), ninguno (a causa del cambio de ácido amino)




                                                                                                                                          73
Recommended INN: List 71                              WHO Drug Information, Vol. 28, No. 1, 2014


 acalisibum
 acalisib                  6-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)ethyl]quinazolin-
                           4(3H)-one

 acalisib                  6-fluoro-3-phényl-2-[(1S)-1-(7H-purin-6-ylamino)éthyl]quinazolin-
                           4(3H)-one

 acalisib                  6-fluoro-3-fenil-2-[(1S)-1-(7H-purin-6-ilamino)etil]quinazolin-
                           4(3H)-ona

                           C21H16FN7O

                                                      N
                                                HN
                                            H   CH3        N
                                        N
                                                 N     N
                                                 H
                                            N
                           F
                                        O




 aftobetinum
 aftobetin                 2-[2-(2-methoxyethoxy)ethoxy]ethyl (2E)-2-cyano-3-[6-(piperidin-
                           1-yl)naphthalen-2-yl]prop-2-enoate

 aftobétine                (2E)-2-cyano-3-[6-(pipéridin-1-yl)naphtalén-2-yl]prop-2-énoate de
                           2-[2-(2-méthoxyéthoxy)éthoxy]éthyle

 aftobetina                (2E)-2-ciano-3-[6-(piperidin-1-il)naftalen-2-il]prop-2-enoato de
                           2-[2-(2-metoxietoxi)etoxi]etilo

                           C26H32N2O5                                    1208971-05-4

                                                           O
                                                                     O
                                                               O              O
                                                      CN                            O
                                N                                                       CH3




 alicdamotidum
 alicdamotide              human kinetochore protein Nuf2 (cell division cycle-associated
                           protein 1)-(55-64)-peptide

 alicdamotide              protéine cinétochore Nuf2 humaine (protéine 1 associée au cycle de
                           la division cellulaire)-(55-64)-peptide

 alicdamotida              proteína humana de cinetocoro Nuf2 (proteína 1 asociada al ciclo de
                           división celular)-(55-64)-péptido

                           C54H80N14O13

                           Sequence / Séquence / Secuencia
                           VYGIRLEHF 9




74
WHO Drug Information, Vol. 28, No. 1, 2014                                              Recommended INN: List 71




 anetumabum ravtansinum #
 anetumab ravtansine                         immunoglobulin G1-lambda2, anti-[Homo sapiens MSLN
                                             (mesothelin, pre-pro-megakaryocyte-potentiating factor,
                                             megakaryocyte potentiating factor, MPF, CAK1)], Homo sapiens
                                             monoclonal antibody conjugated to maytansinoid DM4;
                                             gamma1 heavy chain (1-450) [Homo sapiens VH (IGHV5-51*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-
                                             218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS (449-
                                             450)) (121-450)], (223-216')-disulfide with lambda light chain (1'-
                                             217') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.60%) -IGLJ2*01)
                                             [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')]; dimer (229-
                                             229'':232-232'')-bisdisulfide; conjugated, on an average of 3 lysyl, to
                                                                    2'           2'
                                             maytansinoid DM4 [N -deacetyl-N -(4-mercapto-4-methyl-
                                             1-oxopentyl)-maytansine] via the reducible SPDB linker
                                             [N-succinimidyl 4-(2-pyridyldithio)butanoate]
                                             For the ravtansine part, please refer to the document "INN for
                                             pharmaceutical substances: Names for radicals, groups and others"*

 anétumab ravtansine                         immunoglobuline G1-lambda2, anti-[Homo sapiens MSLN
                                             (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte,
                                             facteur de potentialisation des mégacaryocytes, MPF, CAK1)], Homo
                                             sapiens anticorps monoclonal conjugué au maytansinoïde DM4;
                                             chaîne lourde gamma1 (1-450) [Homo sapiens VH (IGHV5-51*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-
                                             218), charnière (219-233), CH2 (234-343), CH3 (344-448), CHS
                                             (449-450)) (121-450)], (223-216')-disulfure avec la chaîne légère
                                             lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.60%)
                                             -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')];
                                             dimère 229-229'':232-232'')-bisdisulfure; conjugué, sur 3 lysyl en
                                                                                   2'           2'
                                             moyenne, au maytansinoïde DM4 [N -déacétyl-N -(4-mercapto-
                                             4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible
                                             [4-(2-pyridyldithio)butanoate de N-succinimidyle]
                                             Pour la partie ravtansine, veuillez-vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.

 anetumab ravtansina                         inmunoglobulina G1-lambda2, anti-[MSLN de Homo sapiens
                                             (mesotelina, factor de potenciación del pre-pro-megacariocito, factor
                                             de potenciación de megacariocitos, MPF, CAK1)], anticuerpo
                                             monoclonal de Homo sapiens conjugado con el maitansinoide DM4;
                                             cadena pesada gamma1 (1-450) [Homo sapiens VH (IGHV5-51*01
                                             (94.90%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -IGHG1*01 (CH1 (121-
                                             218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS (449-
                                             450)) (121-450)], (223-216')-disulfuro con la cadena ligera lambda
                                             (1'-217') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.60%) -
                                             IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 A43>G (155) (112'-217')];
                                             dimère 229-229'':232-232'')-bisdisulfuro; conjugado, en tres restos
                                                                                                  2'
                                             lisil por término medio, con el maitansinoide DM4 [N -desacetil-
                                                2'
                                             N -(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el
                                             conector SPDB reducible [4-(2-piridilditio)butanoato de
                                             N-succinimidilo]
                                             La información sobre la ravtansina, la encontrarán en el documento
                                             "INN for pharmaceutical substances: Names for radicals, groups and
                                             others"*.




                                                                                                                   75
Recommended INN: List 71                                          WHO Drug Information, Vol. 28, No. 1, 2014



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVELVQSGAE VKKPGESLKI SCKGSGYSFT                       SYWIGWVRQA         PGKGLEWMGI         50
                           IDPGDSRTRY SPSFQGQVTI SADKSISTAY                       LQWSSLKASD         TAMYYCARGQ        100
                           LYGGTYMDGW GQGTLVTVSS ASTKGPSVFP                       LAPSSKSTSG         GTAALGCLVK        150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                       GLYSLSSVVT         VPSSSLGTQT        200
                           YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                       PCPAPELLGG         PSVFLFPPKP        250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                       YVDGVEVHNA         KTKPREEQYN        300
                           STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                       LPAPIEKTIS         KAKGQPREPQ        350
                           VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                       AVEWESNGQP         ENNYKTTPPV        400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                       MHEALHNHYT         QKSLSLSPGK        450

                           Light chain / Chaîne légère / Cadena ligera
                           DIALTQPASV SGSPGQSITI SCTGTSSDIG                       GYNSVSWYQQ         HPGKAPKLMI 50
                           YGVNNRPSGV SNRFSGSKSG NTASLTISGL                       QAEDEADYYC         SSYDIESATP 100
                           VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                       QANKATLVCL         ISDFYPGAVT 150
                           VAWKGDSSPV KAGVETTTPS KQSNNKYAAS                       SYLSLTPEQW         KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                                   217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96         147-203       264-324    370-428
                                                 22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 22'-90' 139'-198'
                                                22'''-90''' 139'''-198'''
                           Inter-H-L (h 5-CL 126) 223-216' 223''-216'''
                           Inter-H-H (h 11, h 14) 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''

                           For the ravtansine part, please refer to the document "INN for pharmaceutical substances: Names for radicals,
                           groups and others"*
                           Pour la partie ravtansine, veuillez vous référer au document "INN for pharmaceutical substances: Names for
                           radicals, groups and others"*.
                           Para la fracción ravtansina, se pueden dirigir al documento "INN for pharmaceutical substances: Names for
                           radicals, groups and others"*.



 anifrolumabum #
 anifrolumab               immunoglobulin G1-kappa, anti-[Homo sapiens IFNAR1 (interferon
                           alpha, beta and omega receptor 1, interferon alpha/beta receptor 1)],
                           Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-
                           215), hinge (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S
                           (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-
                           215')-disulfide with kappa light chain (1'-215') [Homo sapiens
                           V-KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; dimer (226-226'':229-229'')-bisdisulfide

 anifrolumab               immunoglobuline G1-kappa, anti-[Homo sapiens IFNAR1 (récepteur
                           1 de l'interféron alpha, bêta and oméga, récepteur de l'interféron
                           alpha/bêta)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-
                           215), charnière (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S
                           (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-
                           215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens
                           V- KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; dimère (226-226'':229-229'')-bisdisulfure

 anifrolumab               inmunoglobulina G1-kappa, anti-[IFNAR1 de Homo sapiens
                           (receptor 1 de interferón alfa, beta and omega, receptor de interferón
                           alfa/beta)], anticuerpo monoclonal de Homo sapiens ;
                           cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ2*01) [8.8.10] (1-117) -IGHG1*01 (CH1 (118-
                           215), bisagra (216-230), CH2 L1.3>F (234), L1.2>E (235), P116>S
                           (331) (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-
                           215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens
                           V- KAPPA (IGKV3-20*01 (94.70%) -IGKJ5*01) [7.3.9] (1'-108') -
                           IGKC*01 (109'-215')]; dímero (226-226'':229-229'')-bisdisulfuro



76
WHO Drug Information, Vol. 28, No. 1, 2014                                                             Recommended INN: List 71



                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVQSGAE VKKPGESLKI SCKGSGYIFT                  NYWIAWVRQM       PGKGLESMGI        50
                                             IYPGDSDIRY SPSFQGQVTI SADKSITTAY                  LQWSSLKASD       TAMYYCARHD       100
                                             IEGFDYWGRG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                             PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                             NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                  APEFEGGPSV       FLFPPKPKDT       250
                                             LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                             RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  SIEKTISKAK       GQPREPQVYT       350
                                             LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                             DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSFFAWYQQK       PGQAPRLLIY 50
                                             GASSRATGIP DRLSGSGSGT DFTLTITRLE                  PEDFAVYYCQ       QYDSSAITFG 100
                                             QGTRLEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96         144-200       261-321 367-425
                                                                   22''-96'' 144''-200'' 261''-321'' 367''-425''
                                             Intra-L (C23-C104) 23'-89' 135'-195'
                                                                  23'''-89''' 135'''-195'''
                                             Inter-H-L (h 5-CL 126) 220-215' 220''-215'''
                                             Inter-H-H (h 11, h 14) 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             297, 297''



 artefenomelum
 artefenomel                                 4-{2-{4-(cis-dispiro[adamantane-2,3'-[1,2,4]trioxolane-
                                             5',1''-cyclohexane]-4''-yl)phenoxy]ethyl}morpholine

 artéfénomel                                 4-{2-{4-(cis-dispiro[adamantane-2,3'-[1,2,4]trioxolane-
                                             5',1''-cyclohexane]-4''-yl)phénoxy]éthyl}morpholine

 artefenomel                                 4-{2-{4-(cis-diespiro[adamantano-2,3'-[1,2,4]trioxolano-
                                             5',1''-ciclohexano]-4''-il)fenoxi]etil}morfolina

                                             C28H39NO5

                                                         O
                                                     O                   H
                                                                                                         O
                                                         O
                                                                                                 N
                                                                                       O

 asapiprantum
 asapiprant                                  2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-
                                             2-yl)oxy]benzenesulfonyl}piperazin-1-yl)phenoxy]acetic acid

 asapiprant                                  acide 2-[2-(oxazol-2-yl)-5-(4-{4-[(propan-
                                             2-yl)oxy]benzènesulfonyl}pipérazin-1-yl)phénoxy]acétique

 asapiprant                                  ácido 2-[2-(oxazol-2-il)-5-(4-{4-[(propan-
                                             2-il)oxi]bencenosulfonil}piperazin-1-il)fenoxi]acético

                                             C24H27N3O7S

                                                                     O O
                                                                      S
                                                   CH3                  N
                                                                                   N               O         CO2H
                                             H3C         O
                                                                                                         N

                                                                                                     O



                                                                                                                                          77
Recommended INN: List 71                                   WHO Drug Information, Vol. 28, No. 1, 2014


 axelopranum
 axelopran                 3-{(1R,3r,5S)-8-(2-{cyclohexylmethyl[(2S)-2,3-
                           dihydroxypropanoyl]amino}ethyl)-8-azabicyclo[3.2.1]octan-
                           3-yl}benzamide

 axélopran                 3-[(1R,3r,5S)-8-(2-{(cyclohexylméthyl)[(2S)-2,3-
                           dihydroxypropanoyl]amino}éthyl)-8-azabicyclo[3.2.1]octan-
                           3-yl]benzamide

 axeloprán                 3-{(1R,3r,5S)-8-(2-{ciclohexilmetil[(2S)-2,3-
                           dihidroxipropanoil]amino}etil)-8-azabiciclo[3.2.1]octan-3-il}benzamida

                           C26H39N3O4



                                               H                         H OH
                                                                 N              OH
                                    O                  N
                                          H
                                                                     O
                           H2N
                                                           H




 basimglurantum
 basimglurant              2-chloro-4-{2-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-
                           4-yl]ethynyl}pyridine

 basimglurant              2-chloro-4-{2-[1-(4-fluorophényl)-2,5-diméthyl-1H-imidazol-
                           4-yl]éthynyl}pyridine

 basimglurant              2-cloro-4-{2-[1-(4-fluorofenil)-2,5-dimetil-1H-imidazol-4-il]etin-
                           1-il}piridina

                           C18H13ClFN3

                               Cl

                           N
                                               CH3

                                                                     F
                                                   N
                                           N
                                                   CH3


 binimetinibum
 binimetinib               5-[(4-bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-
                           1-methyl-1H-benzimidazole-6-carboxamide

 binimétinib               5-[(4-bromo-2-fluorophényl)amino]-4-fluoro-N-(2-hydroxyéthoxy)-
                           1-méthyl-1H-benzimidazole-6-carboxamide

 binimetinib               5-[(4-bromo-2-fluorofenil)amino]-4-fluoro-N-(2-hidroxietoxi)-1-metil-
                           1H-benzoimidazol-6-carboxamida




78
WHO Drug Information, Vol. 28, No. 1, 2014                                                              Recommended INN: List 71


                                             C17H15BrF2N4O3

                                                                             H
                                                                     O       N            OH
                                                    F                            O
                                                                 H
                                                                 N


                                             Br                  F               N CH3
                                                                         N


 ceralifimodum
 ceralifimod                                 1-({6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-
                                             3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid

 céralifimod                                 acide 1-({6-[(2-méthoxy-4-propylphényl)méthoxy]-1-méthyl-
                                             3,4-dihydronaphtalén-2-yl}méthyl)azétidine-3-carboxylique

 ceralifimod                                 ácido 1-({1-metil-6-[(2-metoxi-4-propilfenil)metoxi]-
                                             3,4-dihidronaftalen-2-il}metil)azetidina-3-carboxílico

                                             C27H33NO4

                                                                                          CH3

                                                                                                            N

                                                                                                                CO2H
                                                                             O

                                             H3C                         OCH3

 ceritinibum
                                                             2
 ceritinib                                   5-chloro-N -{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-
                                               4
                                             N -[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine
                                                             2
 céritinib                                   5-chloro-N -{5-méthyl-4-(pipéridin-4-yl)-2-[(propan-2-yl)oxy]phényl}-
                                               4
                                             N -[2-(propane-2-sulfonyl)phényl]pyrimidine-2,4-diamine
                                                         2
 ceritinib                                   5-cloro-N -{5-metil-4-(piperidin-4-il)-2-[(propan-2-il)oxi]fenil}-
                                               4
                                             N -[2-(propano-2-sulfonil)fenil]pirimidina-2,4-diamina

                                             C28H36ClN5O3S

                                                                                                      CH3
                                                                                              O
                                                                                          O       S     CH3
                                                                         H           H
                                                   H3C                   N       N   N

                                                                             N
                                                                         O           Cl
                                             HN
                                                                 H3C         CH3

 codrituzumabum #
 codrituzumab                                immunoglobulin G1-kappa, anti-[Homo sapiens GPC3 (glypican 3)],
                                             humanized monoclonal antibody;
                                             gamma1 heavy chain (1-445) [humanized VH (Homo sapiens
                                             IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8] (1-115) -Homo
                                             sapiens IGHG1*01 (CH1 (116-213, hinge (214-228), CH2 (229-338),
                                             CH3 (339-443), CHS (444-445)) (116-445)], (218-219')-disulfide with
                                             kappa light chain (1'-219') [humanized V-KAPPA (Homo sapiens
                                             IGKV2-28*01 (86.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens
                                             IGKC*01 (113'-219')]; dimer (224-224":227-227")-bisdisulfide


                                                                                                                              79
Recommended INN: List 71                                        WHO Drug Information, Vol. 28, No. 1, 2014




 codrituzumab                 immunoglobuline G1-kappa, anti-[Homo sapiens GPC3 (glypicane
                              3)], anticorps monoclonal humanisé;
                              chaîne lourde gamma1 (1-445) [VH humanisé (Homo sapiens
                              (Homo sapiens IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8]
                              (1-115) -Homo sapiens IGHG1*01 (CH1 (116-213, charnière (214-
                              228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)],
                              (218-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA
                              humanisé (Homo sapiens IGKV2-28*01 (86.00%) -IGKJ2*01)
                              [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (224-
                              224":227-227")-bisdisulfure

 codrituzumab                 inmunoglobulina G1-kappa, anti-[GPC3 (glipicano 3) de Homo
                              sapiens], anticuerpo monoclonal humanizado;
                              cadena pesada gamma1 (1-445) [VH humanizado (Homo sapiens
                              (Homo sapiens IGHV1-46*01 (82.70%) -(IGHD)-IGHJ5*02) [8.8.8]
                              (1-115) -Homo sapiens IGHG1*01 (CH1 (116-213, bisagra (214-
                              228), CH2 (229-338), CH3 (339-443), CHS (444-445)) (116-445)],
                              (218-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA
                              humanizado (Homo sapiens IGKV2-28*01 (86.00%) -IGKJ2*01)
                              [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];dímero (224-
                              224":227-227")-bisdisulfuro

                              Heavy chain / Chaîne lourde / Cadena pesada
                              QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  DYEMHWVRQA       PGQGLEWMGA        50
                              LDPKTGDTAY SQKFKGRVTL TADKSTSTAY                  MELSSLTSED       TAVYYCTRFY       100
                              SYTYWGQGTL VTVSSASTKG PSVFPLAPSS                  KSTSGGTAAL       GCLVKDYFPE       150
                              PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSS       LGTQTYICNV       200
                              NHKPSNTKVD KKVEPKSCDK THTCPPCPAP                  ELLGGPSVFL       FPPKPKDTLM       250
                              ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV                  EVHNAKTKPR       EEQYNSTYRV       300
                              VSVLTVLHQD WLNGKEYKCK VSNKALPAPI                  EKTISKAKGQ       PREPQVYTLP       350
                              PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE                  SNGQPENNYK       TTPPVLDSDG       400
                              SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                  HNHYTQKSLS       LSPGK            445

                              Light chain / Chaîne légère / Cadena ligera
                              DVVMTQSPLS LPVTPGEPAS ISCRSSQSLV                  HSNRNTYLHW       YLQKPGQSPQ 50
                              LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCSQNTHVP 100
                              PTFGQGTKLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                              VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                              VTHQGLSSPV TKSFNRGEC                                                          219

                              Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                              Intra-H (C23-C104) 22-96          142-198       259-319   365-423
                                                    22''-96'' 142''-198'' 259''-319'' 365''-423''
                              Intra-L (C23-C104) 23'-93'        139'-199'
                                                    23'''-93''' 139'''-199'''
                              Inter-H-L (h 5-CL 126) 218-219' 218''-219'''
                              Inter-H-H (h 11, h 14) 224-224'' 227-227''

                              N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                              H CH2 N84.4:
                              295, 295''



 coltuximabum ravtansinum #
 coltuximab ravtansine        immunoglobulin G1-kappa, anti-[Homo sapiens CD19 (B lymphocyte
                              surface antigen B4, Leu-12)], chimeric monoclonal antibody
                              conjugated to maytansinoid DM4;
                              gamma1 heavy chain (1-450) [Mus musculus VH (IGHV1-69*02 -
                              (IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*01 (CH1
                              (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS
                              (449-450)) (121-450)], (223-211')-disulfide with kappa light chain (1'-
                              211') [Mus musculus V-KAPPA (IGKV4-70*01 -IGKJ1*01) [5.3.7] (1'-
                              104') -Homo sapiens IGKC*01 (105'-211')]; dimer (229-229'':232-
                              232'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to
                                                      2'          2'
                              maytansinoid DM4 [N -deacetyl-N -(4-mercapto-4-methyl-
                              1-oxopentyl)-maytansine] via the reducible SPDB linker [N-
                              succinimidyl 4-(2-pyridyldithio)butanoate]
                              For the ravtansine part, please refer to the document "INN for
                              pharmaceutical substances: Names for radicals, groups and others"*


80
WHO Drug Information, Vol. 28, No. 1, 2014                                                            Recommended INN: List 71


 coltuximab ravtansine                       immunoglobuline G1-kappa, anti-[Homo sapiens CD19 (antigène de
                                             surface B4 des lymphocytes B, Leu-12)], anticorps monoclonal
                                             chimérique conjugué au maytansinoïde DM4;
                                             chaîne lourde gamma1 (1-450) [Mus musculus VH (IGHV1-69*02 -
                                             (IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*01 (CH1
                                             (121-218), charnière (219-233), CH2 (234-343), CH3 (344-448),
                                             CHS (449-450)) (121-450)], (223-211')-disulfure avec la chaîne
                                             légère kappa (1'-211') [Mus musculus V-KAPPA (IGKV4-70*01 -
                                             IGKJ1*01) [5.3.7] (1'-104') -Homo sapiens IGKC*01 (105'-211')];
                                             dimère (229-229'':232-232'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en
                                                                                   2'           2'
                                             moyenne, au maytansinoïde DM4 [N -déacétyl-N -(4-mercapto-
                                             4-méthyl-1-oxopentyl)-maytansine] via le linker SPDB réductible [4-
                                             (2-pyridyldithio)butanoate de N-succinimidyle]
                                             Pour la partie ravtansine, veuillez-vous référer au document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.

 coltuximab ravtansina                       inmunoglobulina G1-kappa, anti-[CD19 de Homo sapiens (antígeno
                                             de superficie B4 de los linfocitos B, Leu-12)], anticuerpo monoclonal
                                             quimérico conjugado con el maitansinoide DM4;
                                             cadena pesada gamma1 (1-450) [Mus musculus VH (IGHV1-69*02 -
                                             (IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens IGHG1*01 (CH1
                                             (121-218), bisagra (219-233), CH2 (234-343), CH3 (344-448), CHS
                                             (449-450)) (121-450)], (223-211')-disulfuro con la cadena ligera
                                             kappa (1'-211') [Mus musculus V-KAPPA (IGKV4-70*01 -IGKJ1*01)
                                             [5.3.7] (1'-104') -Homo sapiens IGKC*01 (105'-211')]; dímero (229-
                                             229'':232-232'')-bisdisulfuro;conjugado en 3 -4 restos lisil por término
                                                                                    2'           2'
                                             medio, con el maitansinoide DM4 [N -desacetil-N -(4-mercapto-
                                             4-metil-1-oxopentil)-maitansina] mediante un conector SPDB
                                             reducible [4-(2-piridilditio)butanoato de N-succinimidilo]
                                             La información sobre la ravtansina, la encontrarán en el documento
                                             "INN for pharmaceutical substances: Names for radicals, groups and
                                             others"*.

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVQPGAE VVKPGASVKL SCKTSGYTFT                  SNWMHWVKQA       PGQGLEWIGE        50
                                             IDPSDSYTNY NQNFQGKAKL TVDKSTSTAY                  MEVSSLRSDD       TAVYYCARGS       100
                                             NPYYYAMDYW GQGTSVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                                             YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                                             KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                                             STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                                             VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                                             LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450


                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVLTQSPAI MSASPGERVT MTCSASSGVN                  YMHWYQQKPG       TSPRRWIYDT 50
                                             SKLASGVPAR FSGSGSGTDY SLTISSMEPE                  DAATYYCHQR       GSYTFGGGTK 100
                                             LEIKRTVAAP SVFIFPPSDE QLKSGTASVV                  CLLNNFYPRE       AKVQWKVDNA 150
                                             LQSGNSQESV TEQDSKDSTY SLSSTLTLSK                  ADYEKHKVYA       CEVTHQGLSS 200
                                             PVTKSFNRGE C                                                                  211

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96         147-203       264-324    370-428
                                                                   22''-96'' 147''-203'' 264''-324'' 370''-428''
                                             Intra-L (C23-C104) 23'-87' 131'-191'
                                                                  23'''-87''' 131'''-191'''
                                             Inter-H-L (h 5-CL 126) 223-211' 223''-211'''
                                             Inter-H-H (h 11, h 14) 229-229'' 232-232''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             300, 300''
                                             For the ravtansine part, please refer to the document "INN for pharmaceutical substances:
                                             Names for radicals, groups and others"*
                                             Pour la partie ravtansine, veuillez vous référer au document "INN for pharmaceutical
                                             substances: Names for radicals, groups and others"*.
                                             Para la fracción ravtansina, se pueden dirigir al documento "INN for pharmaceutical
                                             substances: Names for radicals, groups and others"*.




                                                                                                                                          81
Recommended INN: List 71                                            WHO Drug Information, Vol. 28, No. 1, 2014


 damoctocogum alfa pegolum #
 damoctocog alfa pegol         recombinant DNA derived pegylated B domain deleted human blood
                               coagulation factor VIII (single protein chain) analogue, produced in
                               BHK21 cells (glycoform alfa):
                               des-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-
                               methoxypoly(oxyethylene)]propoxy}propyl)amino]-3-oxopropyl}-
                               2,5-dioxopyrrolidin-3-yl)-L-cysteine](K>C)]human coagulation factor
                               VIII

 damoctocog alfa pégol         analogue du facteur de coagulation sanguine VIII humain amputé du
                               domaine B (une seule chaîne protéique), produit par des cellules
                               BHK21 à partir d'ADN recombinant (glycoforme alfa) :
                               dès-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-
                               méthoxypoly(oxyéthylène)]propoxy}propyl)amino]-3-oxopropyl}-
                               2,5-dioxopyrrolidin-3-yl)-L-cystéine](K>C)]facteur VIII de coagulation
                               humain

 damoctocog alfa pegol         análogo del factor VIII de coagulación humano privado del domanio
                               B (una sola cadena proteica), producido por células BHK21 a partir
                               de ADN recombinante (glicoforma alfa) :
                               des-(743-1636)-[1804-[S-(1-{3-[(3-{2,3-bis[ω-
                               metoxipoli(oxietileno)]propoxi}propil)amino]-3-oxopropil}-
                               2,5-dioxopirrolidin-3-il)-L-cisteina](K>C)]factor VIII de coagulación
                               humano
                               Single chain protein / Protéine monocaténaire / Proteína monocatenaria (1438 AA)
                               ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
                               FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
                               VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
                               PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
                               VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
                               KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
                               MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
                               TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
                               APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
                               PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
                               FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
                               LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
                               VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
                               VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
                               GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SF                                  742
                                                                                         SQNP PVLKRHQREI 1650
                               TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEDENQSPRS FQKKTRHYFI 1700
                               AAVERLWDYG MSSSPHVLRN RAQSGSVPQF KKVVFQEFTD GSFTQPLYRG 1750
                               ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
                               EPRCNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
                               LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
                               APCNIQMEDP TFKENYRFHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
                               ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFETVEMLP SKAGIWRVEC 2000
                               LIGEHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS GQYGQWAPKL 2050
                               ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100
                               FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
                               LHPTHYSIRS TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF 2200
                               ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
                               LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TPVVNSLDPP 2300
                               LLTRYLRIHP QSWVHQIALR MEVLGCEAQD LY                                             2332

                               Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                               153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

                               Modified residues / Résidus modifiés / Restos modificados

                                                 Y                         HO        O
                                346 , 718 , 719 , 723 , 1664 , 1680              S                      H   NH2
                                                                              O O
                                              O-sulfoTyr                                                    CO2H
                                                                                                        O                 O
                                                                           H3CO
                                                   C                                         O                                H
                                                                                                 n HN                 N
                                                  1804                                                                            S
                                                                                     O
                                             S-(pegol)Cys         H3CO                                                        H
                                                                                         n                        O
                                                                                                                          H2N         CO2H
                                                                                             O

                                 Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
                                 Asn-41 Asn-239 Asn-1810 Asn-2118



82
WHO Drug Information, Vol. 28, No. 1, 2014                                                   Recommended INN: List 71




 dasabuvirum
 dasabuvir                                   N-(6-{3-tert-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]-
                                             2-methoxyphenyl}naphthalen-2-yl)methanesulfonamide

 dasabuvir                                   N-(6-{3-tert-butyl-5-[2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl]-
                                             2-méthoxyphényl}naphtalén-2-yl)méthanesulfonamide

 dasabuvir                                   N-(6-{3-terc-butil-5-[2,4-dioxo-3,4-dihidropirimidin-1(2H)-il]-
                                             2-metoxifenil}naftalen-2-il)metanosulfonamida

                                             C26H27N3O5S

                                                                                     H
                                             O                                       N       CH3
                                                                                         S
                                                 HN       N                          O O

                                                      O
                                                                   OCH3
                                                                 CH3
                                                          H3C
                                                                CH3

 decoglurantum
 decoglurant                                 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-
                                             a]pyrimidin-3-yl]ethynyl]pyridin-2-amine

 décoglurant                                 5-(2-{7-(trifluorométhyl)-5-[4-(trifluorométhyl)phényl]pyrazolo[1,5-
                                             a]pyrimidin-3-yl}ethynyl)pyridin-2-amine

 decoglurant                                 5-(2-{7-(trifluorometil)-5-[4-(trifluorometil)fenil]pirazolo[1,5-a]pirimidin-
                                             3-il}etinil)piridin-2-amina

                                             C21H11F6N5
                                                                               CF3



                                             H2N

                                                      N                N

                                                                           N
                                                                               CF3
                                                                       N

 dianexinum #
 dianexin                                    recombinant DNA derived annexin A5 dimer covalently linked by a
                                             14 residues peptide linker, produced in Escherichia coli
                                             (nonglycosylated):
                                             L-methionyl-human annexin A5 fusion protein with glycyl-L-seryl-
                                             L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phenylalanyl-
                                             L-glutaminylglycyl-L-prolyl-L-serylglycyl-L-lysyl-L-leucyl-human
                                             annexin A5

 dianexine                                   dimère de l'annexine A5 liées de façon covalente par une chaîne
                                             peptidique de 14 acides aminés, produit par Escherichia coli à partir
                                             d'ADN recombinant (non glycosylé) :
                                             L-méthionyl-annexine A5 humaine protéine de fusion avec la glycyl-
                                             L-séryl-L-leucyl-L-α-glutamyl-L-valyl-L-leucyl-L-phénylalanyl-
                                             L-glutaminylglycyl-L-prolyl-L-sérylglycyl-L-lysyl-L-leucyl-annexine A5
                                             humaine




                                                                                                                         83
Recommended INN: List 71                                 WHO Drug Information, Vol. 28, No. 1, 2014


     dianexina             dímero de la anexina A5 covalentemente unido por una cadena
                           peptídica de 14 aminoácidos, producido por Escherichia coli a partir
                           de ADN recombinante (no glicosilado) :
                           L-metionil-anexina A5 humana proteína de fusión con la glicil-L-seril-
                           L-leucil-L-α-glutamil-L-valil-L-leucil-L-fenilalanil-L-glutaminilglicil-
                           L-prolil-L-serilglicil-L-lisil-L-leucil-anexina A5 humana


                           Sequence / Séquence / Secuencia
                           MAQVLRGTVT DFPGFDERAD AETLRKAMKG               LGTDEESILT          LLTSRSNAQR   50
                           QEISAAFKTL FGRDLLDDLK SELTGKFEKL               IVALMKPSRL          YDAYELKHAL   100
                           KGAGTNEKVL TEIIASRTPE ELRAIKQVYE               EEYGSSLEDD          VVGDTSGYYQ   150
                           RMLVVLLQAN RDPDAGIDEA QVEQDAQALF               QAGELKWGTD          EEKFITIFGT   200
                           RSVSHLRKVF DKYMTISGFQ IEETIDRETS               GNLEQLLLAV          VKSIRSIPAY   250
                           LAETLYYAMK GAGTDDHTLI RVMVSRSEID               LFNIRKEFRK          NFATSLYSMI   300
                           KGDTSGDYKK ALLLLCGEDD GSLEVLFQGP               SGKLAQVLRG          TVTDFPGFDE   350
                           RADAETLRKA MKGLGTDEES ILTLLTSRSN               AQRQEISAAF          KTLFGRDLLD   400
                           DLKSELTGKF EKLIVALMKP SRLYDAYELK               HALKGAGTNE          KVLTEIIASR   450
                           TPEELRAIKQ VYEEEYGSSL EDDVVGDTSG               YYQRMLVVLL          QANRDPDAGI   500
                           DEAQVEQDAQ ALFQAGELKW GTDEEKFITI               FGTRSVSHLR          KVFDKYMTIS   550
                           GFQIEETIDR ETSGNLEQLL LAVVKSIRSI               PAYLAETLYY          AMKGAGTDDH   600
                           TLIRVMVSRS EIDLFNIRKE FRKNFATSLY               SMIKGDTSGD          YKKALLLLCG   650
                           EDD                                                                             653

                           Modified residues / Résidus modifiés / Restos modificados
                                     K = N6-acetylLys                         Y = phosphoTyr
                           70-76-79-97-101-403-409-412-430-434                    94-427
                                O
                                      NH            H                     O                    H
                              H3C                                   O P
                                             H2N      CO2H                OH           H2 N     CO2H
                                                                        OH



 dinutuximabum #
 dinutuximab               immunoglobulin G1-kappa, anti-ganglioside GD2, chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-443) [Mus musculus VH (IGHV1S135*01 -
                           (IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens IGHG1*03 (CH1
                           (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS
                           (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-
                           220') [Mus musculus V-KAPPA (IGKV1-110*01 -IGKJ5*01) 11.3.10]
                           (1'-113') -Homo sapiens IGKC*01 (114'-220')]; dimer (222-222'':225-
                           225'')-bisdisulfide

 dinutuximab               immunoglobuline G1-kappa, anti-ganglioside GD2, anticorps
                           monoclonal chimérique;
                           chaîne lourde gamma1 (1-443) [Mus musculus VH (IGHV1S135*01 -
                           (IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens IGHG1*03 (CH1
                           (114-222), charnière (223-237), CH2 (238-347), CH3 (348-452),
                           CHS (453-454)) (125-454)], (216-220')-disulfure avec la chaîne
                           légère kappa (1'-220') [Mus musculus V-KAPPA (IGKV1-110*01 -
                           IGKJ5*01) 11.3.10] (1'-113') -Homo sapiens IGKC*01 (114'-220')];
                           dimère (222-222'':225-225'')-bisdisulfure

 dinutuximab               inmunoglobulina G1-kappa, anti-gangliósido GD2, anticuerpo
                           monoclonal quimérico;
                           cadena pesada gamma1 (1-443) [Mus musculus VH
                           (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo sapiens
                           IGHG1*03 (CH1 (114-222), bisagra (223-237), CH2 (238-347), CH3
                           (348-452), CHS (453-454)) (125-454)], (216-220')-disulfuro con la
                           cadena ligera kappa (1'-220') [Mus musculus V-KAPPA (IGKV1-
                           110*01 -IGKJ5*01) 11.3.10] (1'-113') -Homo sapiens IGKC*01 (114'-
                           220')]; dímero(222-222'':225-225'')-bisdisulfuro




84
WHO Drug Information, Vol. 28, No. 1, 2014                                                            Recommended INN: List 71




                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLLQSGPE LEKPGASVMI SCKASGSSFT                  GYNMNWVRQN       IGKSLEWIGA        50
                                             IDPYYGGTSY NQKFKGRATL TVDKSSSTAY                  MHLKSLTSED       SAVYYCVSGM       100
                                             EYWGQGTSVT VSSASTKGPS VFPLAPSSKS                  TSGGTAALGC       LVKDYFPEPV       150
                                             TVSWNSGALT SGVHTFPAVL QSSGLYSLSS                  VVTVPSSSLG       TQTYICNVNH       200
                                             KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL                  LGGPSVFLFP       PKPKDTLMIS       250
                                             RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV                  HNAKTKPREE       QYNSTYRVVS       300
                                             VLTVLHQDWL NGKEYKCKVS NKALPAPIEK                  TISKAKGQPR       EPQVYTLPPS       350
                                             REEMTKNQVS LTCLVKGFYP SDIAVEWESN                  GQPENNYKTT       PPVLDSDGSF       400
                                             FLYSKLTVDK SRWQQGNVFS CSVMHEALHN                  HYTQKSLSLS       PGK              443

                                             Light chain / Chaîne légère / Cadena ligera
                                             EIVMTQSPAT LSVSPGERAT LSCRSSQSLV                  HRNGNTYLHW       YLQKPGQSPK 50
                                             LLIHKVSNRF SGVPDRFSGS GSGTDFTLKI                  SRVEAEDLGV       YFCSQSTHVP 100
                                             PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                                             KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                                             EVTHQGLSSP VTKSFNRGEC                                                         220

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          140-196       257-317   363-421
                                                                   22''-96'' 140''-196'' 257''-317'' 363''-421''
                                             Intra-L (C23-C104) 23'-93'        140'-200'
                                                                   23'''-93''' 140'''-200'''
                                             Inter-H-L (h 5-CL 126) 216-220' 216''-220'''
                                             Inter-H-H (h 11-h 14)       222-222'' 225-225''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             293, 293''




 doravirinum
 doravirine                                  3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-
                                             3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-
                                             3-yl}oxy)benzonitrile

 doravirine                                  3-chloro-5-({1-[(4-méthyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-
                                             3-yl)méthyl]-2-oxo-4-(trifluorométhyl)-1,2-dihydropyridin-
                                             3-yl}oxy)benzonitrile

 doravirina                                  3-cloro-5-({1-[(4-metil-5-oxo-4,5-dihidro-1H-1,2,4-triazol-3-il)metil]-
                                             2-oxo-4-(trifluorometil)-1,2-dihidropiridin-3-il}oxi)benzonitrilo

                                             C17H11ClF3N5O3

                                                                     O
                                                   N                      O               CN
                                                                 N
                                             HN
                                                       N
                                                           CH3            CF3
                                               O
                                                                                  Cl


 eldelumabum #
 eldelumab                                   immunoglobulin G1-kappa, anti-[Homo sapiens CXCL10 (chemokine
                                             C-X-C motif ligand 10, 10 kDa interferon gamma-induced protein
                                             gamma-IP10, IP-10, INP10, small inducible cytokine B10, SCYB10)],
                                             Homo sapiens monoclonal antibody;gamma1 heavy chain (1-454)
                                             [Homo sapiens VH (IGHV3-33*01 (89.80%) -(IGHD)-IGHJ6*01)
                                             [8.8.17] (1-124) -IGHG1*01 (CH1 (125-222), hinge (223-237), CH2
                                             (238-347), CH3 (348-452), CHS (453-454)) (125-454)], (227-216')-
                                             disulfide with kappa light chain (1'-216') [Homo sapiens V-KAPPA
                                             (IGKV3-20*01 (100.00%) -IGKJ3*01) [7.3.10] (1'-109') -IGKC*01
                                             (110'-216')]; dimer (233-233'':236-236'')-bisdisulfide




                                                                                                                                           85
Recommended INN: List 71                                         WHO Drug Information, Vol. 28, No. 1, 2014


 eldélumab                 immunoglobuline G1-kappa, anti-[Homo sapiens CXCL10
                           (chémokine C-X-C motif ligand 10, protéine gamma-IP10 de 10 kDa
                           induite par l'interféron gamma, IP-10, INP10, petite cytokine
                           inductible B10, SCYB10)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-454) [Homo sapiens VH (IGHV3-33*01
                           (89.80%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -IGHG1*01 (CH1 (125-
                           222), charnière (223-237), CH2 (238-347), CH3 (348-452), CHS
                           (453-454)) (125-454)], (227-216')-disulfure avec la chaîne légère
                           kappa (1'-216') [Homo sapiens V- KAPPA (IGKV3-20*01 (100.00%) -
                           IGKJ3*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimère (233-
                           233'':236-236'')-bisdisulfure

 eldelumab                 inmunoglobulina G1-kappa, anti-[CXCL10 de Homo sapiens
                           (quimioquina C-X-C motivo ligando 10, proteína gamma-IP10 de 10
                           kDa inducida por el interferón gamma, IP-10, INP10, pequeña
                           citoquina inducible B10, SCYB10)], anticuerpo monoclonal de Homo
                           sapiens;
                           cadena pesada gamma1 (1-454) [Homo sapiens VH (IGHV3-33*01
                           (89.80%) -(IGHD)-IGHJ6*01) [8.8.17] (1-124) -IGHG1*01 (CH1 (125-
                           222), bisagra (223-237), CH2 (238-347), CH3 (348-452), CHS (453-
                           454)) (125-454)], (227-216')-disulfuro con la cadena ligera kappa (1'-
                           216') [Homo sapiens V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ3*01)
                           [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimero (233-233'':236-236'')-
                           bisdisulfuro


                           Heavy chain / Chaîne lourde / Cadena pesada
                           QMQLVESGGG VVQPGRSLRL SCTASGFTFS                  NNGMHWVRQA       PGKGLEWVAV        50
                           IWFDGMNKFY VDSVKGRFTI SRDNSKNTLY                  LEMNSLRAED       TAIYYCAREG       100
                           DGSGIYYYYG MDVWGQGTTV TVSSASTKGP                  SVFPLAPSSK       STSGGTAALG       150
                           CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                           GTQTYICNVN HKPSNTKVDK RVEPKSCDKT                  HTCPPCPAPE       LLGGPSVFLF       250
                           PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                  KFNWYVDGVE       VHNAKTKPRE       300
                           EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKALPAPIE       KTISKAKGQP       350
                           REPQVYTLPP SREEMTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                           TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                           SPGK                                                                                454

                           Light chain / Chaîne légère / Cadena ligera
                           EIVLTQSPGT LSLSPGERAT LSCRASQSVS                  SSYLAWYQQK       PGQAPRLLIY 50
                           GASSRATGIP DRFSGSGSGT DFTLTISRLE                  PEDFAVYYCQ       QYGSSPIFTF 100
                           GPGTKVDIKR TVAAPSVFIF PPSDEQLKSG                  TASVVCLLNN       FYPREAKVQW 150
                           KVDNALQSGN SQESVTEQDS KDSTYSLSST                  LTLSKADYEK       HKVYACEVTH 200
                           QGLSSPVTKS FNRGEC                                                             216

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          151-207       268-328   374-432
                                                 22''-96'' 151''-207'' 268''-328'' 374''-432''
                           Intra-L (C23-C104) 23'-89'        136'-196'
                                                 23'''-89''' 136'''-196'''
                           Inter-H-L (h 5-CL 126) 227-216' 227''-216'''
                           Inter-H-H (h 11, h 14) 233-233'' 236-236''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           304, 304''


 eluxadolinum
 eluxadoline               5-({[(2S)-2-amino-3-(4-carbamoyl-
                           2,6-dimethylphenyl)propanoyl][(1S)-1-(4-phenyl-1H-imidazol-
                           2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid

 éluxadoline               acide 5-({[(2S)-2-amino-3-(4-carbamoyl-
                           2,6-diméthylphényl)propanoyl][(1S)-1-(4-phényl-1H-imidazol-
                           2-yl)éthyl]amino}méthyl)-2-méthoxybenzoïque

 eluxadolina               ácido 5-({[(2S)-2-amino-3-(4-carbamoil-
                           2,6-dimetilfenil)propanoil][(1S)-1-(4-fenil-1H-imidazol-
                           2-il)etil]amino}metil)-2-metoxibenzoico




86
WHO Drug Information, Vol. 28, No. 1, 2014                                                     Recommended INN: List 71


                                             C32H35N5O5




                                                                         N       NH
                                                        CH3         O
                                                                                     CH3
                                                                         N
                                                                                 H
                                             H2 N                H NH2                     CO2H
                                                                CH3
                                                    O
                                                                                           OCH3


 encorafenibum
 encorafenib                                 methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-
                                             3-(methanesulfonamido)phenyl]}-1-(propan-2-yl)-1H-pyrazol-
                                             4-yl}pyrimidin-2-yl)amino]propan-2-yl}carbamate

 encorafénib                                 N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3-(méthanesulfonamido)phényl]}-
                                             1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-
                                             2-yl}carbamate de méthyle

 encorafenib                                 N-{(2S)-1-[(4-{3-[5-cloro-2-fluoro-3-(metanosulfonamido)fenil]}-
                                             1-(propan-2-il)-1H-pirazol-4-il}pirimidin-2-il)amino]propan-
                                             2-il}carbamato de metilo

                                             C22H27ClFN7O4S

                                                                                     H CH3 O
                                                                             H
                                                                    N        N                        CH3
                                                           Cl                              N      O
                                                                                           H
                                                                         N
                                                O O
                                                 S
                                             H3C   N
                                                   H
                                                           F      N N
                                                                             CH3
                                                                    H3C


 enfortumabum vedotinum #
 enfortumab vedotin                          immunoglobulin G1-kappa, anti-[Homo sapiens PVRL4 (poliovirus
                                             receptor-related 4, nectin-4, nectin 4, PPR4, LNIR], Homo sapiens
                                             monoclonal antibody conjugated to auristatin E;
                                             gamma1 heavy chain (1-447) [Homo sapiens VH (IGHV3-48*02
                                             (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-
                                             215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-
                                             447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214')
                                             [Homo sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01) [6.3.9]
                                             (1'-107') -IGKC*01 (108'-214')]; dimer (226-226'':229-229'')-
                                             bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to
                                             monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-
                                             valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-cit-PABC) linker
                                             For the vedotin part, please refer to the document "INN for
                                             pharmaceutical substances: Names for radicals, groups and
                                             others"*.




                                                                                                                     87
Recommended INN: List 71                                                  WHO Drug Information, Vol. 28, No. 1, 2014


 enfortumab védotine       immunoglobuline G1-kappa, anti-[Homo sapiens PVRL4 (membre 4 de
                           la famille du récepteur du poliovirus, nectine-4, nectine 4, PPR4,
                           LNIR], Homo sapiens anticorps monoclonal conjugué à l'auristatine E;
                           chaîne lourde gamma1 (1-447) [Homo sapiens VH (IGHV3-48*02
                           (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-
                           215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-
                           447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-
                           214') [Homo sapiens V- KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (226-226'':229-229'')-
                           bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne, au
                           monométhylauristatine E (MMAE), via un linker clivable
                           maléimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-cit-
                           PABC)
                           Pour la partie védotine, veuillez-vous référer au document "INN for
                           pharmaceutical substances: Names for radicals, groups and others"*.

 enfortumab vedotina       inmunoglobulina G1-kappa, anti-[PVRL4 de Homo sapiens (miembro 4
                           de la familia del receptor de poliovirus, nectina-4, nectina 4, PPR4,
                           LNIR], anticuerpo monoclonal de Homo sapiens conjugado con
                           auristatina E;
                           cadena pesada gamma1 (1-447) [Homo sapiens VH (IGHV3-48*02
                           (98.00%) -(IGHD)-IGHJ6*01) [8.8.10] (1-117) -IGHG1*03 (CH1 (118-
                           215), bisagra(216-230), CH2 (231-340), CH3 (341-445), CHS (446-
                           447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-
                           214') [Homo sapiens V-KAPPA (IGKV1-12*01 (96.80%) -IGKJ4*01)
                           [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (226-226'':229-229'')-
                           bisdisulfuro; conjugado, en 3- 4 restos cisteinil por término medio, con
                           monometilauristatinea E (MMAE), mediante un conector escindible
                           maleimidocaproil-valil-citrulinil-p-aminobencilcarbamato (mc-val-cit-
                           PABC)
                           La información sobre la vedotina, la encontrarán en el documento
                           "INN for pharmaceutical substances: Names for radicals, groups and
                           others"*.
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVQPGGSLRL SCAASGFTFS                          SYNMNWVRQA      PGKGLEWVSY      50
                           ISSSSSTIYY ADSVKGRFTI SRDNAKNSLS                          LQMNSLRDED      TAVYYCARAY     100
                           YYGMDVWGQG TTVTVSSAST KGPSVFPLAP                          SSKSTSGGTA      ALGCLVKDYF     150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                          SLSSVVTVPS      SSLGTQTYIC     200
                           NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                          APELLGGPSV      FLFPPKPKDT     250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                          GVEVHNAKTK      PREEQYNSTY     300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                          PIEKTISKAK      GQPREPQVYT     350
                           LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                          WESNGQPENN      YKTTPPVLDS     400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                          ALHNHYTQKS      LSLSPGK        447

                           Light chain / Chaîne légère / Cadena ligera
                           DIQMTQSPSS VSASVGDRVT ITCRASQGIS                          GWLAWYQQKP      GKAPKFLIYA 50
                           ASTLQSGVPS RFSGSGSGTD FTLTISSLQP                          EDFATYYCQQ      ANSFPPTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                          SVVCLLNNFY      PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                          LSKADYEKHK      VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                                      214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          144-200       261-321   367-425
                                                 22''-96'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 23'-88'        134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) * 220-214' 220''-214'''
                           Inter-H-H (h 11, h 14) * 226-226'' 229-229''
                           *Two or three of the inter-chain disulfide bridges are not present, an average of 3 to 4
                            cysteinyl being conjugated each to a drug linker.
                           *Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 à 4 cystéinyl en
                            moyenne étant chacun conjugué à un linker-principe actif.
                           *Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 a 4 cisteinil está
                           conjugada a conectores de principio activo.

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''
                           For the vedotin part, please refer to the document "INN for pharmaceutical substances:
                           Names for radicals, groups and others"*
                           Pour la partie védotine, veuillez vous référer au document "INN for pharmaceutical
                           substances: Names for radicals, groups and others"*.
                           Para la fracción vedotina, se pueden dirigir al documento "INN for pharmaceutical
                           substances: Names for radicals, groups and others"   *.


88
WHO Drug Information, Vol. 28, No. 1, 2014                                                  Recommended INN: List 71


 fevipiprantum
 fevipiprant                                 2-(1-{[4-methanesulfonyl-2-(trifluoromethyl)phenyl]methyl}-2-methyl-
                                             1H-pyrrolo[2,3-b]pyridin-3-yl)acetic acid

 févipiprant                                 acide 2-(1-{[4-méthanesulfonyl-2-(trifluorométhyl)phényl]méthyl}-
                                             2-méthyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acétique

 fevipiprant                                 ácido 2-(1-{[4-metanosulfonil-2-(trifluorometil)fenil]metil}-2-metil-
                                             1H-pirrolo[2,3-b]piridin-3-il)acético

                                             C19H17F3N2O4S

                                                               CO2H


                                                               CH3
                                               N       N
                                                                                CH3
                                                                            S
                                                                                O
                                                       F3C                  O

 filanesibum
 filanesib                                   (2S)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-
                                             2-phenyl-1,3,4-thiadiazole-3(2H)-carboxamide

 filanésib                                   (2S)-2-(3-aminopropyl)-5-(2,5-difluorophényl)-N-méthoxy-N-méthyl-
                                             2-phényl-1,3,4-thiadiazole-3(2H)-carboxamide

 filanesib                                   (2S)-2-(3-aminopropil)-5-(2,5-difluorofenil)-2-fenil-N-metil-N-metoxi-
                                             1,3,4-tiadiazol-3(2H)-carboxamida

                                             C20H22F2N4O2S

                                               F
                                                           H3C          O
                                                                   N        CH3
                                                           N
                                                               N        O
                                               F       S                        NH2




 galunisertibum
 galunisertib                                4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
                                             3-yl]quinoline-6-carboxamide

 galunisertib                                4-[2-(6-méthylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-
                                             3-yl]quinoléine-6-carboxamide

 galunisertib                                4-[2-(6-metilpiridin-2-il)-5,6-dihidro-4H-pirrolo[1,2-b]pirazol-
                                             3-il]quinolina-6-carboxamida

                                             C22H19N5O

                                                                    N

                                             H2N

                                                   O
                                                                                N
                                                                   N N                CH3



                                                                                                                      89
Recommended INN: List 71                                      WHO Drug Information, Vol. 28, No. 1, 2014


 guselkumabum #
 guselkumab                immunoglobulin G1-lambda2, anti-[Homo sapiens IL23 (interleukin
                           23, IL-23)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -
                           IGHG1*01 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3
                           (341-444), CHS (445-446)) (118-446)], (220-216')-disulfide with
                           lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV1-
                           40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')];
                           dimer (226-226'':229-229'')-bisdisulfide

 guselkumab                immunoglobuline G1-lambda2, anti-[Homo sapiens IL23 (interleukine
                           23, IL-23)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -
                           IGHG1*01 (CH1 (118-215), charnière (216-230), CH2 (231-340),
                           CH3 (341-444), CHS (445-446)) (118-446)], (220-216')-disulfure
                           avec la chaîne légère lambda (1'-217') [Homo sapiens V-LAMBDA
                           (IGLV1-40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01
                           (112'-217')]; dimère (226-226'':229-229'')-bisdisulfure

 guselkumab                inmunoglobulina G1-lambda2, anti-[IL23 (interleukina 23, IL-23) de
                           Homo sapiens], anticuerpo monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV5-51*01
                           (93.90%) -(IGHD)-IGHJ3*01 M123>L (112)) [8.8.10] (1-117) -
                           IGHG1*01 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3
                           (341-444), CHS (445-446)) (118-446)], (220-216')-disulfuro con la
                           cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-
                           40*01 (91.80%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')];
                           dímero (226-226'':229-229'')-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGESLKI SCKGSGYSFS                  NYWIGWVRQM       PGKGLEWMGI        50
                           IDPSNSYTRY SPSFQGQVTI SADKSISTAY                  LQWSSLKASD       TAMYYCARWY       100
                           YKPFDVWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                           PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                           NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                           LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                           RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                           LPPSRDELTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                           DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPG           446

                           Light chain / Chaîne légère / Cadena ligera
                           QSVLTQPPSV SGAPGQRVTI SCTGSSSNIG                  SGYDVHWYQQ       LPGTAPKLLI 50
                           YGNSKRPSGV PDRFSGSKSG TSASLAITGL                  QSEDEADYYC       ASWTDGLSLV 100
                           VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                           VAWKADSSPV KAGVETTTPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                            217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          144-200       261-321   367-425
                                                 22''-96'' 144''-200'' 261''-321'' 367''-425''
                           Intra-L (C23-C104) 22'-90'         139'-198'
                                                 22'''-90''' 139'''-198'''
                           Inter-H-L (h 5-CL 126) 220-216' 220''-216'''
                           Inter-H-H (h 11, h 14) 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           297, 297''

 idarucizumabum #
 idarucizumab              immunoglobulin Fab G1-kappa, anti-[dagibatran], humanized
                           monoclonal antibody;
                           VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH
                           (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16]
                           (1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), hinge 1-5 (221-
                           225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219')
                           [humanized V-KAPPA (Homo sapiens IGKV2-30*01 (88.00%) -
                           IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]



90
WHO Drug Information, Vol. 28, No. 1, 2014                                                            Recommended INN: List 71




 idarucizumab                                immunoglobuline Fab G1-kappa, anti-[dagibatran], anticorps
                                             monoclonal humanisé;
                                             chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé
                                             (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16]
                                             (1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), charnière 1-5
                                             (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère
                                             kappa (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*01
                                             (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                             (113'-219')]

 idarucizumab                                inmunoglobulina Fab G1-kappa, anti-[dagibatrán], anticuerpo
                                             monoclonal humanizado;
                                             cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado
                                             (Homo sapiens IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16]
                                             (1-122) -Homo sapiens IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-
                                             225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa
                                             (1'-219') [V-KAPPA humanizado (Homo sapiens IGKV2-30*01
                                             (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                             (113'-219')]

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQESGPG LVKPSETLSL TCTVSGFSLT                  SYIVDWIRQP       PGKGLEWIGV 50
                                             IWAGGSTGYN SALRSRVSIT KDTSKNQFSL                  KLSSVTAADT       AVYYCASAAY 100
                                             YSYYNYDGFA YWGQGTLVTV SSASTKGPSV                  FPLAPSSKST       SGGTAALGCL 150
                                             VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                  SSGLYSLSSV       VTVPSSSLGT 200
                                             QTYICNVNHK PSNTKVDKKV EPKSC                                                   225

                                             Light chain / Chaîne légère / Cadena ligera
                                             DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL                  YTDGKTYLYW       FLQRPGQSPR 50
                                             RLIYLVSKLD SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCLQSTHFP 100
                                             HTFGGGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                             VTHQGLSSPV TKSFNRGEC                                                          219

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-95 149-205
                                             Intra-L (C23-C104) 23'-93' 139'-199'
                                             Inter-H-L (h 5-CL 126) 225-219'

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             None - Aucun - Ninguno




 ipafriceptum #
 ipafricept                                  fusion protein for immune applications (FPIA) comprising Homo
                                             sapiens FZD8 (frizzled family receptor 8, Frizzled-8) extracellular
                                             domain, fused with Homo sapiens immunoglobulin G1 Fc fragment;
                                             Homo sapiens FZD8 precursor fragment 28-158 (1-131) -Homo
                                             sapiens IGHG1*01 H-CH2-CH3 fragment (hinge 1-15 C5>S (136)
                                             (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363)) (132-
                                             363); dimer (142-142':145-145')-bisdisulfide

 ipafricept                                  protéine de fusion pour applications immunitaires (FPIA) comprenant
                                             le domaine extracellulaire d'Homo sapiens FZD8 (membre 8 de la
                                             famille de récepteurs frizzled, Frizzled-8), fusionné au fragment Fc
                                             de l'Homo sapiens immunoglobuline G1;
                                             Homo sapiens FZD8 fragment 28-158 du précurseur (1-131) -Homo
                                             sapiens IGHG1*01 fragment H-CH2-CH3 (charnière 1-15 C5>S
                                             (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-363))
                                             (132-363); dimère (142-142':145-145')-bisdisulfure




                                                                                                                                           91
Recommended INN: List 71                                            WHO Drug Information, Vol. 28, No. 1, 2014


 ipafricept                proteína de fusión para aplicaciones inmunitarias (que comprende el
                           dominio extracelular de FZD8 de Homo sapiens (miembro 8 de la
                           familia de receptores frizzled, Frizzled-8), fusionado con el
                           fragmento Fc de inmunoglobulina G1 de Homo sapiens;
                           fragmento precursor 28-158 (1-131) de FZD8 de Homo sapiens -
                           Homo sapiens IGHG1*01 fragmento H-CH2-CH3 (bisagra 1-15
                           C5>S (136) (132-146), CH2 (147-256), CH3 (257-361), CHS (362-
                           363)) (132-363); dímero(142-142':145-145')-bisdisulfuro


                           Fused chain / chaine fusionnée / cadena fusionada
                           ASAKELACQE ITVPLCKGIG YNYTYMPNQF NHDTQDEAGL                         EVHQFWPLVE           50
                           IQCSPDLKFF LCSMYTPICL EDYKKPLPPC RSVCERAKAG                         CAPLMRQYGF          100
                           AWPDRMRCDR LPEQGNPDTL CMDYNRTDLT TEPKSSDKTH                         TCPPCPAPEL          150
                           LGGPSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK                         FNWYVDGVEV          200
                           HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS                         NKALPAPIEK          250
                           TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP                         SDIAVEWESN          300
                           GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS                         CSVMHEALHN          350
                           HYTQKSLSLS PGK                                                                          363

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intrachain FZD8          8-69 16-62 53-91 80-121 84-108
                                                    8'-69' 16'-62' 53'-91' 80'-121' 84'-108'
                                       C23-C104 177-237 283-341
                                                    177'-237' 283'-341'
                           Interchain h 11, h 14 142-142' 145-145'

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           22, 125, 22', 125': bi-, tri- and tetra-antennary oligosaccharides containing up to 4 sialic acids
                           213, 213' (CH2 N84.4): complex biantennary oligosaccharide

                           Post-translational modifications/ modifications post-traductionnelles / modificaciones post-traduccionales
                           363, 363': C-terminal K processed by carboxypeptidase-like activity




 ledipasvirum
 ledipasvir                methyl [(1S)-1-{(1R,3S,4S)-3-[5-(9,9-difluoro-7-{2-[(6S)-5-{(2S)-2-
                           [(methoxycarbonyl)amino]-3-methylbutanoyl}-5-azaspiro[2.4]hept-
                           6-yl]-1H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzimidazol-2-yl]-
                           2-azabicyclo[2.2.1]heptane-2-carbonyl}-2-methylpropyl]carbamate

 lédipasvir                [(1S)-1-{(1R,3S,4S)-3-[5-(9,9-difluoro-7-{2-[(6S)-5-{(2S)-2-
                           [(méthoxycarbonyl)amino]-3-méthylbutanoyl}-5-azaspiro[2.4]hept-
                           6-yl]-1H-imidazol-4-yl}-9H-fluorén-2-yl)-1H-benzimidazol-2-yl]-
                           2-azabicyclo[2.2.1]heptane-2-carbonyl}-2-méthylpropyl]carbamate
                           de méthyle

 ledipasvir                [(1S)-1-{(1R,3S,4S)-3-[5-(9,9-difluoro-7-{2-[(6S)-5-{(2S)-2-
                           [(metoxicarbonil)amino]-3-metilbutanoil}-5-azaespiro[2.4]hept-6-il]-
                           1H-imidazol-4-yl}-9H-fluoren-2-il)-1H-benzimidazol-2-il]-
                           2-azabiciclo[2.2.1]heptano-2-carbonil}-2-metilpropil]carbamato de
                           metilo

                           C49H54F2N8O6

                                       CH3
                                                H
                                                N         OCH3                                        H H
                               H3 C                                                                   N
                                       H                             F
                                                     O          F
                                                                                                                    N      H
                                       N        O                                                     N    H              H CH3
                                                N                                                              O
                                      H                                                                        O         NH     CH3
                                           HN

                                                                                                                    OCH3




92
WHO Drug Information, Vol. 28, No. 1, 2014                                               Recommended INN: List 71


 lexanopadolum
 lexanopadol                                 trans-6'-fluoro-N-methyl-4-phenyl-4',9'-dihydro-
                                             3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

 lexanopadol                                 trans-6'-fluoro-N-méthyl-4-phényl-4',9'-dihydro-
                                             3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine

 lexanopadol                                 trans-6'-fluoro-N-metil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-
                                             1,1'-pirano[3,4-b]indol]-4-amina

                                             C23H25FN2O


                                                           H
                                                           N
                                                    H3 C

                                                      H
                                                      N
                                                               O




                                             F


 liafensinum
 liafensine                                  6-[(4S)-2-methyl-4-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-
                                             7-yl]pyridazin-3-amine

 liafensine                                  6-[(4S)-2-méthyl-4-(naphtalén-2-yl)-1,2,3,4-tétrahydroisoquinolin-
                                             7-yl]pyridazin-3-amine

 liafensina                                  6-[(4S)-2-metil-4-(naftalen-2-il)-1,2,3,4-tetrahidroisoquinolin-
                                             7-il]piridazin-3-amina

                                             C24H22N4

                                             H2 N

                                                     N                      CH3
                                                           N            N



                                                                   H




 margetuximabum #
 margetuximab                                immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (epidermal
                                             growth factor receptor 2, HER-2, p185c-erbB2, NEU, EGFR2)],
                                             chimeric monoclonal antibody;
                                             gamma1 heavy chain (1-450) [Mus musculus VH (IGHV14-3*02 -
                                             (IGHD)-IGHJ4*01) [8.8.13] (1-120) - Homo sapiens IGHG1*01 (CH1
                                             K120>R (217) (121-218), hinge (219-233), CH2 L1.2>V (238), F7>L
                                             (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L (399)
                                             (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with
                                             kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV6-17*01 -
                                             IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                                             dimer (229-229'':232-232'')-bisdisulfide



                                                                                                                     93
Recommended INN: List 71                                     WHO Drug Information, Vol. 28, No. 1, 2014




 margétuximab              immunoglobuline G1-kappa, anti-[Homo sapiens ERBB2 (récepteur
                           2 du facteur de croissance épidermique, HER-2, p185c-erbB2, NEU,
                           EGFR2)], anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-450) [Mus musculus VH (IGHV14-3*02 -
                           (IGHD)-IGHJ4*01) [8.8.13] (1-120) - Homo sapiens IGHG1*01 (CH1
                           K120>R (217) (121-218), charnière (219-233), CH2 L1.2>V (238),
                           F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L
                           (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure
                           avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA
                           (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dimère (229-229'':232-232'')-bisdisulfure

 margetuximab              inmunoglobulina G1-kappa, anti-[ERBB2 de Homo sapiens (receptor
                           2 del factor de crecimiento epidérmico, HER-2, p185c-erbB2, NEU,
                           EGFR2)], anticuerpo monoclonal quimérico;
                           cadena pesada gamma1 (1-450) [Mus musculus VH (IGHV14-3*02 -
                           (IGHD)-IGHJ4*01) [8.8.13] (1-120) - Homo sapiens IGHG1*01 (CH1
                           K120>R (217) (121-218),bisagra (219-233), CH2 L1.2>V (238),
                           F7>L (246), R83>P (295), Y85.2>L (303) (234-343), CH3 P83>L
                           (399) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro
                           con la cadena ligera kappa (1'-214') [Mus musculus V-KAPPA
                           (IGKV6-17*01 -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dímero (229-229'':232-232'')-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQQSGPE LVKPGASLKL SCTASGFNIK                  DTYIHWVKQR       PEQGLEWIGR        50
                           IYPTNGYTRY DPKFQDKATI TADTSSNTAY                  LQVSRLTSED       TAVYYCSRWG       100
                           GDGFYAMDYW GQGASVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                           YICNVNHKPS NTKVDKRVEP KSCDKTHTCP                  PCPAPELVGG       PSVFLLPPKP       250
                           KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPPEEQYN       300
                           STLRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                           VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPLV       400
                           LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQSHKF MSTSVGDRVS ITCKASQDVN                  TAVAWYQQKP       GHSPKLLIYS 50
                           ASFRYTGVPD RFTGSRSGTD FTFTISSVQA                  EDLAVYYCQQ       HYTTPPTFGG 100
                           GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          147-203 264-324        370-428
                                                 22''-96'' 147''-203'' 264''-324'' 370''-428''
                           Intra-L (C23-C104) 23'-88'         134'-194'
                                                 23'''-88''' 134'''-194'''
                           Inter-H-L (h 5-CL 126) 223-214' 223''-214'''
                           Inter-H-H (h 11, h 14) 229-229'' 232-232''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           300, 300''



 mavatrepum
 mavatrep                  2-[2-(2-{(1E)-2-(trifluoromethyl)phenyl]ethenyl}-1H-benzimidazol-
                           5-yl)phenyl]propan-2-ol

 mavatrep                  2-[2-(2-{(1E)-2-(trifluorométhyl)phényl]éthényl}-1H-benzimidazol-
                           5-yl)phényl]propan-2-ol

 mavatrep                  2-[2-(2-{(1E)-2-(trifluorometil)fenil]etenil}-1H-benzoimidazol-
                           5-il)fenil]propan-2-ol




94
WHO Drug Information, Vol. 28, No. 1, 2014                                              Recommended INN: List 71


                                             C25H21F3N2O

                                              H3C                   H
                                                     OH             N
                                             H3C

                                                                    N                  CF3



 methylsamidorphani chloridum
 methylsamidorphan chloride                  (17R)-3-carbamoyl-17-(cyclopropylmethyl)-4,14-dihydroxy-
                                             17-methyl-6-oxomorphinan-17-ium chloride

 chlorure de méthylsamidorphan               chlorure de (17R)-3-carbamoyl-17-(cyclopropylméthyl)-
                                             4,14-dihydroxy-17-méthyl-6-oxomorphinanium

 cloruro de metilsamidorfano                 cloruro de (17R)-3-carbamoil-17-(ciclopropilmetil)-4,14-dihidroxi-
                                             17-metil-6-oxomorfinanio

                                             C22H29ClN2O4
                                                           H3C
                                                           H N

                                                          HO
                                                                            Cl


                                             H2N          OH            O
                                                    O

 mirogabalinum
 mirogabalin                                 [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-
                                             6-yl]acetic acid

 mirogabaline                                acide [(1R,5S,6S)-6-(aminométhyl)-3-éthylbicyclo[3.2.0]hept-3-én-
                                             6-yl]acétique

 mirogabalina                                ácido 2-[(1R,5S,6S)-6-(aminometil)-3-etilbiciclo[3.2.0]hept-3-en-
                                             6-il]acético

                                             C12H19NO2

                                                                   NH2
                                                          H
                                             H3C

                                                                    CO2H
                                                          H

 neboterminum #
 nebotermin                                  recombinant DNA derived L-methionyl-human bone morphogenetic
                                             protein 2 (BMP-2 or BMP-2A), produced in Escherichia coli
                                             (nonglycosylated)

 nébotermine                                 L-méthionyl-protéine
                                                                2 morphogénétique de l'os humaine (BMP-2 ou
                                             BMP-2A), produite par Escherichia coli (non glycosylée) à partir
                                             d'ADN recombinant

 nebotermina                                 L-metionil-proteína
                                                              2 morfogenética humana de hueso (BMP-2 o
                                             BMP-2A), producida por Escherichia coli (no glicosilada) a partir de
                                             ADN recombinante




                                                                                                                    95
Recommended INN: List 71                                     WHO Drug Information, Vol. 28, No. 1, 2014




                           C1152H1776N322O330S20

                           Monomer / Monomère / Monómero
                                                                                M
                           QAKHKQRKRL KSSCKRHPLY VDFSDVGWND WIVAPPGYHA FYCHGECPFP 50
                           LADHLNSTNH AIVQTLVNSV NSKIPKACCV PTELSAISML YLDENEKVVL 100
                           KNYQDMVVEG CGCR                                        114

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           14-79 14'-79' 43-111 43'-111' 47-113 47'-113' 78-78'




 nobiprostolanum
 nobiprostolan             propan-2-yl (5E)-7-{(1R,2R,3R,5S)-2-[2-(2-heptyl-1,3-dioxolan-
                           2-yl)ethyl]-3,5-dihydroxycyclopentyl}hept-5-enoate

 nobiprostolan             (5E)-7-{(1R,2R,3R,5S)-2-[2-(2-heptyl-1,3-dioxolan-2-yl)éthyl]-
                           3,5-dihydroxycyclopentyl}hept-5-énoate de propan-2-yle

 nobiprostolán             (5E)-7-{(1R,2R,3R,5S)-2-[2-(2-heptil-1,3-dioxolan-2-il)etil]-
                           3,5-dihidroxiciclopentil}hept-5-enoato de propan-2-ilo

                           C27H48O6

                                 OH
                            H         H
                                                                     O        CH3

                                                                 O       CH3
                           HO         H       O      O
                                 H                                       CH3




 ombitasvirum
 ombitasvir                dimethyl N,N'-{[(2S,5S)-1-(4-tert-butylphenyl)pyrrolidene-2,5-diyl]-
                           bis-{[(4,1-phenyleneazanediyl)carbonyl][(2S)-pyrrolidine-
                           2,1-diyl]}[(2S)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate

 ombitasvir                N,N'-{[(2S,5S)-1-(4-tert-butylphényl)pyrrolidine-2,5-diyl]-bis-{[(4,1-
                           phénylèneazanediyl)carbonyl][(2S)-pyrrolidine-2,1-diyl]}[(2S)-3-
                           méthyl-1-oxobutane-1,2-diyl])}biscarbamate de diméthyle

 ombitasvir                N,N'-{[(2S,5S)-1-(4-terc-butilfenil)pirrolideno-2,5-diil]-bis-{[(4,1-
                           fenilenoazanodiil)carbonil][(2S)-pirrolidina-2,1-diil]}[(2S)-3-metil-
                           1-oxobutano-1,2-diil])}biscarbamato de dimetilo

                           C50H67N7O8

                                   O          O                                                     O       O
                                 CH3              CH3            H              H            H3C                CH3
                                          NH O                           N                      O    HN
                           H3C              H                                                       H               CH3
                                 H                                                                              H
                                                     N                                      N
                                 O        N          H                                      H           N       O


                                                                              CH3
                                                                 H3 C
                                                                             CH3




96
WHO Drug Information, Vol. 28, No. 1, 2014                                                            Recommended INN: List 71


 ontuxizumabum #
 ontuxizumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens CD248 (endosialin,
                                             tumor endothelial marker 1, TEM1), humanized/chimeric monoclonal
                                             antibody;
                                             gamma1 heavy chain (1-454) [chimeric VH (Homo sapiens IGHV4-
                                             59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -Homo sapiens
                                             IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3
                                             S85.3>F (410) (348-452), CHS (453-454)) (125-454)], (227-215')-
                                             disulfide with kappa light chain (1'-215') [humanized V-KAPPA
                                             (Homo sapiens IGKV1-33*01 (83.20%) -IGKJ1*01) [6.3.10] (1'-108')
                                             -Homo sapiens IGKC*01 (109'-215')]; dimer (233-233'':236-236'')-
                                             bisdisulfide

 ontuxizumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens CD248
                                             (endosialine, marqueur endothélial tumoral 1, TEM1)], anticorps
                                             monoclonal humanisé/chimérique;
                                             chaîne lourde gamma1 (1-454) [VH chimérique (Homo sapiens
                                             IGHV4-59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -Homo
                                             sapiens IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-
                                             347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)],
                                             (227-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA
                                             humanisé (Homo sapiens IGKV1-33*01 (83.20%) -IGKJ1*01)
                                             [6.3.10] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dimère (233-
                                             233'':236-236'')-bisdisulfure

 ontuxizumab                                 inmunoglobulina G1-kappa, anti-[CD248 de Homo sapiens
                                             (endosialina, marcador endotelial tumoral 1, TEM1)], anticuerpo
                                             monoclonal humanizado/quimérico;
                                             cadena pesada gamma1 (1-454) [VH quimérico (Homo sapiens
                                             IGHV4-59*04 (68.00%) -(IGHD)-IGHJ4*01) [8.8.17] (1-124) -Homo
                                             sapiens IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-
                                             347), CH3 S85.3>F (410) (348-452), CHS (453-454)) (125-454)],
                                             (227-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA
                                             humanizada (Homo sapiens IGKV1-33*01 (83.20%) -IGKJ1*01)
                                             [6.3.10] (1'-108') -Homo sapiens IGKC*01 (109'-215')]; dímero (233-
                                             233'':236-236'')-bisdisulfuro
                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLQESGPG LVRPSQTLSL TCTASGYTFT                  DYVIHWVKQP       PGRGLEWIGY        50
                                             INPYDDDTTY NQKFKGRVTM LVDTSSNTAY                  LRLSSVTAED       TAVYYCARRG       100
                                             NSYDGYFDYS MDYWGSGTPV TVSSASTKGP                  SVFPLAPSSK       STSGGTAALG       150
                                             CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                                             GTQTYICNVN HKPSNTKVDK KVEPKSCDKT                  HTCPPCPAPE       LLGGPSVFLF       250
                                             PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                  KFNWYVDGVE       VHNAKTKPRE       300
                                             EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKALPAPIE       KTISKAKGQP       350
                                             REPQVYTLPP SRDELTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                                             TPPVLDSDGF FFLYSKLTVD KSRWQQGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                                             SPGK                                                                                454

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVT ITCRASQNVG                  TAVAWLQQTP       GKAPKLLIYS 50
                                             ASNRYTGVPS RFSGSGSGTD YTFTISSLQP                  EDIATYYCQQ       YTNYPMYTFG 100
                                             QGTKVQIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          151-207       268-328   374-432
                                                                   22''-96'' 151''-207'' 268''-328'' 374''-432''
                                             Intra-L (C23-C104) 23'-88'        135'-195'
                                                                   23'''-88''' 135'''-195'''
                                             Inter-H-L (h 5-CL 126) 227-215' 227''-215'''
                                             Inter-H-H (h 11, h 14) 233-233'' 236-236''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             304, 304''




                                                                                                                                           97
Recommended INN: List 71                                              WHO Drug Information, Vol. 28, No. 1, 2014


 oreptacogum alfa (activatum) #
 oreptacog alfa (activated)       recombinant DNA derived human blood coagulation factor VIIa (two
                                  protein chains) analogue, produced in CHO cells (glycoform alfa):
                                  [10-L-glutamine(P>Q),32-L-glutamic acid(K>E),34-L-glutamic
                                  acid(A>E),36-L-glutamic acid(R>E),106-L-asparagine(T>N),
                                  253-L-asparagine(V>N)]activated human coagulation factor VII
                                  (proconvertine, SPCA)

 oreptacog alfa (activé)          analogue du facteur de coagulation sanguine VIIa (deux chaînes
                                  protéiques) humain, produit par des cellules ovariennes de hamster
                                  chinois (CHO) à partir d'ADN recombinant (glycoforme alfa) :
                                  [10-L-glutamine(P>Q),32-L-acide glutamique(K>E),34-L-acide
                                  glutamique(A>E),36-L-acide glutamique(R>E),
                                  106-L-asparagine(T>N),253-L-asparagine(V>N)]facteur de
                                  coagulation VII humain activé (proconvertine, SPCA)

 oreptacog alfa (activado)        análogo del factor VIIa de coagulación (dos cadenas proteicas )
                                  humano, producido por células ováricas de hamster chino (CHO) a
                                  partir de ADN recombinante (glicoforma alfa) :
                                  [10-L-glutamina(P>Q),32-L-ácido glutámico(K>E),34-L-ácido
                                  glutámico (A>E),36-L-ácido glutámico(R>E),
                                  106-L-asparagina(T>N),253-L-asparagina(V>N)]factor de
                                  coagulación VII humano activado (proconvertina, SPCA)
                                  Light chain / Chaîne légère / Cadedena ligera
                                  ANAFLEELRQ GSLERECKEE QCSFEEAREI FEDEEETKLF WISYSDGDQC 50
                                  ASSPCQNGGS CKDQLQSYIC FCLPAFEGRN CETHKDDQLI CVNENGGCEQ 100
                                  YCSDHNGTKR SCRCHEGYSL LADGVSCTPT VEYPCGKIPI LEKRNASKPQ 150
                                  GR                                                     152

                                  Heavy chain / Chaîne lourde / Cadena pesada
                                    IVGGKVCP KGECPWQVLL LVNGAQLCGG                  TLINTIWVVS        AAHCFDKIKN      200
                                  WRNLIAVLGE HDLSEHDGDE QSRRVAQVII                  PSTYVPGTTN        HDIALLRLHQ      250
                                  PVNLTDHVVP LCLPERTFSE RTLAFVRFSL                  VSGWGQLLDR        GATALELMVL      300
                                  NVPRLMTQDC LQQSRKVGDS PNITEYMFCA                  GYSDGSKDSC        KGDSGGPHAT      350
                                  HYRGTWYLTG IVSWGQGCAT VGHFGVYTRV                  SQYIEWLQKL        MRSEPRPGVL      400
                                  LRAPFP                                                                              406

                                  Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                  17-22     50-61      55-70     72-81      91-102 98-112
                                  114-127 135-262 159-164 178-194 310-329 340-368

                                  Modified residues / Résidus modifiés / Restos modificados
                                                    E                              HO2C     H   NH2
                                  6-7-14-16-19-20-25-26-29-32-34-35-36
                                              4-carboxyGlu                      HO2C             CO2H

                                  Glycosylation sites (S or N) / Sites de glycosylation (S ou N) / Posiciones de glicosilación (S o N)
                                  Ser-52 Ser-60 Asn-106 Asn-145 Asn-253 Asn-322

 paclitaxelum trevatidum
 paclitaxel trevatide             short modified fragment of human amyloid beta A4 protein covalently
                                  linked to three molecules of paclitaxel through succinyl linkers:
                                    2.1 6.10   6.15
                                  N ,N , N -tris{4-[(1S,2R)-1-benzamido-3-{[(2S,5R,7S,10R,13S)-
                                  10,12-bis(acetyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-epoxytax-
                                  11-en-13-yl]oxy}-3-oxo-1-phenylpropan-2-yl)oxy]-4-oxobutanoyl}
                                                        1                     7
                                  ([318-L-threonine(P>T ),324-L-serine(C>S ),325-L-
                                                  8                 10                  15
                                  arginine(G>R ),327-L-lysine(N>K ),332-L-lysine(N>K )] human
                                  amyloid beta A4 protein precursor-(318-336)-peptide)

 paclitaxel trévatide             fragment court et modifié de la protéine bêta A4 amyloïde humaine
                                  lié de façon covalente à trois molécules de paclitaxel par autant de
                                  succinyles :
                                    2.1  6.10 6.15
                                  N ,N , N -tris{4-[(1S,2R)-1-benzamido-3-{[(2S,5R,7S,10R,13S)-
                                  10,12-bis(acétyloxy)-2-benzoyl-1,7-dihydroxy-9-oxo-5,20-époxytax-
                                  11-en-13-yl]oxy}-3-oxo-1-phénylpropan-2-yl)oxy]-4-oxobutanoyl}
                                                        1                    7
                                  ([318-L-thréonine(P>T ),324-L-sérine(C>S ),325-L-
                                                 8                  10                   15
                                  arginine(G>R ),327-L-lysine(N>K ),332-L-lysine(N>K )] précurseur
                                  de la protéine amyloïde bêta A4 humaine-(318-336)-peptide)


98
WHO Drug Information, Vol. 28, No. 1, 2014                                                                   Recommended INN: List 71


 paclitaxel trevatida                        fragmento corto y modificado de la proteína beta A4 amiloide
                                             humana unido covalentemente a tres moléculas de paclitaxel
                                             mediante succinilos :
                                                2.1 6.10  6.15
                                             N ,N , N -tris{4-[(1S,2R)-1-benzamido-3-{[(2S,5R,7S,10R,13S)-
                                             10,12-bis(acetiloxi)-2-benzoil-1,7-dihidroxi-9-oxo-5,20-epoxitax-11-
                                             en-13-il]oxi}-3-oxo-1-fenilpropan-2-il)oxi]-4-oxobutanoil} ([318-L-
                                                             1                 7                       8
                                             treonina(P>T ),324-L-serina(C>S ),325-L-arginina(G>R ),327-L-
                                                         10                 15
                                             lisina(N>K ),332-L-lisina(N>K )] precursor de la proteína amiloide
                                             beta A4 humana-(318-336)-péptido
                                             C257H308N32O79

                                             Peptide / Peptide / Péptido
                                             TFFYGGSRGK RNNFKTEEY                    19

                                             Modified residues / Résidus modifiés / Restos modificados

                                              K 10, 15                                                       O       CH3
                                                                   R     =       O C
                                                                                                                     H     O
                                             HN               H                                                  O                OH
                                                                                                  O    H3C
                                                  R                                                                            CH3 H
                                                                                          O H
                                                       H2N        CO2H
                                                                                                       O                 CH3
                                               T1                                                                                  H     H
                                                                                                       H                 CH3
                                                                                     HN   H       O
                                                                                              O                                O         O
                                                  R   NH H                                                       OH        H
                                             H3C                                                                         O O       CH3
                                                           CO2H
                                                  H OH
                                                                                                                     O

 palbociclibum
 palbociclib                                 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-
                                             2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one

 palbociclib                                 6-acétyl-8-cyclopentyl-5-méthyl-2-{[5-(pipérazin-1-yl)pyridin-
                                             2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one

 palbociclib                                 6-acetil-8-ciclopentil-5-metil-2-{[5-(piperazin-1-il)piridin-
                                             2-il]amino}pirido[2,3-d]pirimidin-7(8H)-ona

                                             C24H29N7O2

                                                                         H
                                                              N          N       N

                                                                             N                CH3
                                                       N
                                             HN                                  N                    CH3

                                                                                      O       O

 panulisibum
 panulisib                                   2-(5-{(2EZ)-8-[6-amino-5-(trifluoromethyl)pyridin-3-yl]-
                                             2-(cyanoimino)-3-methyl-2,3-dihydro-1H-imidazo[4,5-c]quinolin-
                                             1-yl}pyridin-2-yl)-2-methylpropanenitrile

 panulisib                                   2-(5-{(2EZ)-8-[6-amino-5-(trifluorométhyl)pyridin-3-yl]-
                                             2-(cyanoimino)-3-méthyl-2,3-dihydro-1H-imidazo[4,5-c]quinoléin-
                                             1-yl}pyridin-2-yl)-2-methylpropanenitrile

 panulisib                                   2-(5-{(2EZ)-8-[6-amino-5-(trifluorometil)pyridin-3-il]-2-(cianoimino)-
                                             3-metil-2,3-dihidro-1H-imidazo[4,5-c]quinolin-1-il}piridin-2-il)-
                                             2-metilpropanonitrilo




                                                                                                                                             99
Recommended INN: List 71                                  WHO Drug Information, Vol. 28, No. 1, 2014


                           C27H20F3N9

                                               CN
                                     H3C
                                        H3 C
                                                                 CN
                                               N
                                                             N
                           H2N      N
                                                      N
                                                             N CH
                                                                  3
                           F3C

                                                     N

 patisiranum
 patisiran                 small interfering RNA (siRNA);
                           RNA duplex of guanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-adenylyl-
                           (3'→5')-adenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-
                           (3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-2'-O-methyluridylyl-
                           (3'→5')-adenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-
                           methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-
                           methylcytidylyl-(3'→5')-adenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-
                           thymidylyl-(3'→5')-thymidine with thymidylyl-(5'→3')-thymidylyl-
                           (5'→3')-cytidylyl-(5'→3')-adenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-
                           uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-
                           uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-
                           adenylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-adenylyl-(5'→3')-
                           adenylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-
                           adenosine

 patisiran                 petit ARN interférant (siRNA);
                           duplex ARN du brin guanylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-
                           adénylyl-(3'→5')-adénylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-
                           (3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-2'-O-méthyluridylyl-
                           (3'→5')-adénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-
                           méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-
                           méthylcytidylyl-(3'→5')-adénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-
                           thymidylyl-(3'→5')-thymidine avec le brin anti-sens thymidylyl-
                           (5'→3')-thymidylyl-(5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-2'-O-
                           méthyluridylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-
                           (5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidylyl-(5'→3')-uridylyl-
                           (5'→3')-cytidylyl-(5'→3')-adénylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-
                           adénylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-
                           uridylyl-(5'→3')-adénosine

 patisirán                 ARN interferente pequeño (siRNA);
                           ARN dúplex de la cadena guanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-
                           adenilil-(3'→5')-adenilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-
                           metilcitidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-
                           adenilil-(3'→5')-guanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-adenilil-
                           (3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-
                           metilcitidilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-adenilil-(3'→5')-2'-O-
                           metiluridilil-(3'→5')-timidilil-(3'→5')-timidina con la cadena antisentido
                           timidilil-(5'→3')-timidilil-(5'→3')-citidilil-(5'→3')-adenilil-(5'→3')-2'-O-
                           metiluridilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-
                           uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-uridilil-(5'→3')-citidilil-
                           (5'→3')-adenilil-(5'→3')-2'-O-metiluridilil-(5'→3')-adenilil-(5'→3')-
                           adenilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-
                           adenosina




100
WHO Drug Information, Vol. 28, No. 1, 2014                                                                Recommended INN: List 71


                                             C412H480N148O290P40
                                                     (3'-5')G-U-A-A-C-C-A-A-G-A-G-U-A-U-U-C-C-A-U-dT-dT
                                             (5'-3')dT-dT-C-A-U-U-G-G-U-U-C-U-C-A-U-A-A-G-G-U-A

                                             Modified nucleosides (C and U) / Nucléosides modifiés (C et U) / Nucleósidos modificados (C y U)

                                                C = mC          O        N    NH2          U = mU                 H
                                                                                                          O       N   O
                                                            O        N
                                                HO                                                    O       N
                                                                                           HO

                                                      HO            OCH3
                                                                                                HO         OCH3



 pegbovigrastimum #
 pegbovigrastim                              recombinant DNA derived bovine granulocyte colony-stimulating
                                             factor (G-CSF) analogue, produced in Escherichia coli
                                             (nonglycosylated), covalently bonded to methoxy polyethylene
                                             glycol:
                                             L-methionyl-[133-{4-(1-{[2-({[ω-
                                             methoxypoly(oxyethylene)]carbonyl}amino)ethoxy]imino}ethyl)-
                                             L-phenylalanine(T>F)}]bovine granulocyte colony-stimulating factor
                                             (G-CSF)

 pegbovigrastim                              analogue du facteur de stimulation de colonies de granulocytes
                                             bovin, produit par Escherichia coli à partir d'ADN recombinant (non
                                             glycosylé), auquel est liée de façon covalente une chaîne
                                             méthoxypolyéthylèneglycol :
                                             L-méthionyl-[133-{4-(1-{[2-({[ω-
                                             méthoxypoly(oxyéthylène)]carbonyl}amino)éthoxy]imino}éthyl)-
                                             L-phénylalanine(T>F)}]facteur de stimulation des colonies de
                                             granulocytes (G-CSF) bovin

 pegbovigrastim                              análogo del factor bovino estimulante de colonias de granulocitos,
                                             producido por Escherichia coli a partir de ADN recombinante (no
                                             glicosilado), al cual se une covalentemente una cadena
                                             metoxipolietilenglicol :
                                             L-metionil-[133-{4-(1-{[2-({[ω-
                                             metoxipoli(oxietileno)]carbonil}amino)etoxi]imino}etil)-
                                             L-fenilalanina(T>F)}]factor estimulante de colonias de granulocitos
                                             (G-CSF) bovino

                                             C859H1370N236O248S9 . [C2H4O]n

                                             Sequence / Séquence / Secuencia
                                                                                                                M
                                             TPLGPARSLP        QSFLLKCLEQ        VRKIQADGAE LQERLCAAHK LCHPEELMLL 50
                                             RHSLGIPQAP        LSSCSSQSLQ        LTSCLNQLHG GLFLYQGLLQ ALAGISPELA 100
                                             PTLDTLQLDV        TDFATNIWLQ        MEDLGAAPAV QPFQGAMPTF TSAFQRRAGG 150
                                             VLVASQLHRF        LELAYRGLRY        LAEP                             174

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             36-42 64-74

                                             Modified residue / Résidu modifié / Resto modificado
                                                                O                    CH3
                                             H3CO                            O
                                                           O        N            N                H   NH2
                                                                n   H
                                                                F 133                                     CO2H
                                              4-(methoxyPEGcarbonylaminoethoxyiminoethyl)Phe




                                                                                                                                          101
Recommended INN: List 71                                     WHO Drug Information, Vol. 28, No. 1, 2014


 pegteograstimum #
 pegteograstim             recombinant DNA derived human granulocyte colony-stimulating
                           factor (G-CSF) analogue, produced in Escherichia coli
                           (nonglycosylated), covalently bonded to methoxy polyethylene
                           glycol:
                           endo-139a-S-{(3RS)-1-[3-({3-[ω-
                           methoxypoly(oxyethylene)]propyl}amino)-3-oxopropyl]-
                                                                    137
                           2,5-dioxopyrrolidin-3-yl}-L-cysteine (->C )-des-(37-39)-
                           [1-L-methionine(A>M),18-L-serine(C>S)]human granulocyte colony
                           stimulating factor (G-CSF, pluripoietin)

 pegtéograstim             analogue du facteur humain de stimulation de colonies de
                           granulocytes, produit par Escherichia coli à partir d'ADN
                           recombinant (non glycosylé), auquel est lié de façon covalente une
                           chaîne méthoxypolyéthylèneglycol :
                           endo-139a-S-{(3RS)-1-[3-({3-[ω-
                           méthoxypoly(oxyéthylène)]propyl}amino)-3-oxopropyl]-
                                                                   137
                           2,5-dioxopyrrolidin-3-yl}-L-cystéine(->C )-dès-(37-39)-
                           [1-L-méthionine(A>M),18-L-sérine(C>S)]facteur humain de
                           stimulation de colonies de granulocytes (G-CSF, pluripoïétine)

 pegteograstim             análogo del factor humano estimulante de colonias de granulocitos,
                           producido por Escherichia coli a partir de ADN recombinante (no
                           glicosilado), al que se une covalentemente una cadena
                           metoxipolietilenglicol:
                           endo-139a-S-{(3RS)-1-[3-({3-[ω-metoxipoli(oxietileno)]propil}amino)-
                                                                                137
                           3-oxopropil]-2,5-dioxopirrolidin-3-il}-L-cisteina(->C )-des-(37-39)-
                           [1-L-metionina(A>M),18-L-serina(C>S)]factor humano estimulante de
                           colonias de granulocitos (G-CSF, pluripoyetina)

                           C859H1360N226O249S9 . [C2H4O]n

                           Sequence / Séquence / Secuencia
                           MTPLGPASSL PQSFLLKSLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
                           LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL 100
                           GPTLDTLQLD VADFATTIWQ QMEELGMAPA LQPTQGCAMP AFASAFQRRA 150
                           GGVLVASHLQ SFLEVSYRVL RHLAQP                           176

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           37-43 65-75

                           Modified residue / Résidu modifié / Resto modificado      O              O
                                                                                                        H
                                         C                                      HN              N
                                     137(139a)                                                              S
                                   PEG-linker-Cys            O                                          H
                                                       H3C             O                    O
                                                                           n
                                                                                                    H2N         CO2H



 pevonedistatum
 pevonedistat              [(1S,2S,4R)-4-(4-{[(1S)-2,3-dihydro-1H-inden-1-yl]amino}-
                           7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-hydroxycyclopentyl]methyl
                           sulfamate

 pévonédistat              sulfamate de [(1S,2S,4R)-4-(4-{[(1S)-2,3-dihydro-1H-indén-
                           1-yl]amino}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-
                           2-hydroxycyclopentyl]méthyle

 pevonedistat              sulfamato de (1S,2S,4R)-4-(4-{[(1S)-2,3-dihidro-1H-inden-
                           1-il]amino}-7H-pirrolo[2,3-d]pirimidin-7-il)-2-hidroxiciclopentil]metilo




102
WHO Drug Information, Vol. 28, No. 1, 2014                                                        Recommended INN: List 71


                                             C21H25N5O4S


                                                                          H                    O O
                                                        H
                                                        N             N                         S
                                                                                              O   NH2
                                                        H                                H
                                                             N   N
                                                                                       OH
                                                                                  H


 ralimetinibum
 ralimetinib                                 5-[2-tert-butyl-5-(4-fluorophenyl)-1H-imidazol-4-yl]-
                                             3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine

 ralimétinib                                 5-[2-tert-butyl-5-(4-fluorophényl)-1H-imidazol-4-yl]-
                                             3-(2,2-diméthylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine

 ralimetinib                                 5-[2-terc-butil-5-(4-fluorofenil)-1H-imidazol-4-il]-3-(2,2-dimetilpropil)-
                                             3H-imidazo[4,5-b]piridin-2-amina

                                             C24H29FN6

                                                                              N
                                                                                        NH2
                                              H3 C       N                    N
                                                                  N                     CH3
                                             H3C
                                                     CH3 N                               CH3
                                                         H                        H3C
                                                                              F


 remeglurantum
 remeglurant                                 (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-
                                             3,4-dihydroisoquinolin-2(1H)-yl]methanone

 réméglurant                                 (6-bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-méthyl-
                                             3,4-dihydroisoquinoléin-2(1H)-yl]méthanone

 remeglurant                                 (6-bromopirazolo[1,5-a]pirimidin-2-il)[(1R)-1-metil-
                                             3,4-dihidroisoquinolin-2(1H)-il]metanona

                                             C17H15BrN4O

                                                     H CH3 O

                                                         N
                                                                              N
                                                                 N N


                                                                                  Br


 ricolinostatum
 ricolinostat                                2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-
                                             5-carboxamide

 ricolinostat                                2-(diphénylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-
                                             5-carboxamide

 ricolinostat                                2-(difenilamino)-N-[7-(hidroxiamino)-7-oxoheptil]pirimidina-
                                             5-carboxamida




                                                                                                                       103
Recommended INN: List 71                                         WHO Drug Information, Vol. 28, No. 1, 2014


                           C24H27N5O3




                                        N       N
                                                            H                           H
                                            N               N                           N
                                                                                            OH
                                                        O                           O

 rimegepantum
 rimegepant                (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-
                           5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-
                           b]pyridin-1-yl)piperidine-1-carboxylate

 rimégépant                4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)pipéridine-
                           1-carboxylate de (5S,6S,9R)-5-amino-6-(2,3-difluorophényl)-
                           6,7,8,9-tétrahydro-5H-cyclohepta[b]pyridin-9-yle

 rimegepant                4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-1-il)piperidina-
                           1-carboxilato de (5S,6S,9R)-5-amino-6-(2,3-difluorofenil)-
                           6,7,8,9-tetrahidro-5H-ciclohepta[b]piridin-9-ilo

                           C28H28F2N6O3

                                                                       O
                                                                               NH
                           F
                                                                           N        N
                               F    H
                                    H                   O        N

                                   H2 N                 H
                                                            O
                                                    N


 ripasudilum
 ripasudil                 4-fluoro-5-{[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline

 ripasudil                 4-fluoro-5-{[(2S)-2-méthyl-1,4-diazépan-1-yl]sulfonyl}isoquinoléine

 ripasudil                 4-fluoro-5-{[(2S)-2-metil-1,4-diazepan-1-il]sulfonil}isoquinolina

                           C15H18FN3O2S

                                          F
                           N               O O H CH3
                                            S
                                                N
                                                            NH



 riviciclibum
 riviciclib                2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-
                           1-methylpyrrolidin-3-yl]-4H-1-benzopyran-4-one

 riviciclib                2-(2-chlorophényl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxyméthyl)-
                           1-méthylpyrrolidin-3-yl]-4H-1-benzopyran-4-one

 riviciclib                2-(2-clorofenil)-5,7-dihidroxi-8-[(2R,3S)-2-(hidroximetil)-
                           1-metilpirrolidin-3-il]-4H-1-benzopiran-4-ona




104
WHO Drug Information, Vol. 28, No. 1, 2014                                                                     Recommended INN: List 71




                                             C21H20ClNO5

                                                      CH3
                                                      N             OH
                                                                H       Cl
                                                               H
                                             HO                     O




                                                          OH        O


 rivipanselum
 rivipansel                                  (2S)-3-cyclohexyl-2-([(1R,2R,3S,5R)-2-[(6-deoxy-
                                             α-L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-
                                             4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaphthalene-1-yl)amino]-
                                             6,13-dioxo-2,5-diaza-8,11-dioxatridecanoyl}cyclohexyl]
                                             {2-O-benzoyl-β-D-galactopyranosid-3-O-yl})propanoic acid

 rivipansel                                  acide (2S)-3-cyclohexyl-2-([(1R,2R,3S,5R)-2-[(6-déoxy-
                                             α-L-galactopyranosyl)oxy]-3-(2,6-dioxo-1,2,3,6-tétrahydropyrimidin-
                                             4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaphtalèn-1-yl)amino]-
                                             6,13-dioxo-2,5-diaza-8,11-dioxatridécanoyl}cyclohexyl]
                                             {2-O-benzoyl-β-D-galactopyranosid-3-O-yl})propanoïque

 rivipansel                                  ácido (2S)-3-ciclohexil-2-([(1R,2R,3S,5R)-2-[(6-desoxi-
                                             α-L-galactopiranosil)oxi]-3-(2,6-dioxo-1,2,3,6-tetrahidropirimidin-
                                             4-carboxamido)-5-{13-[(3,6,8-trisulfonatonaftalen-1-il)amino]-
                                             6,13-dioxo-2,5-diaza-8,11-dioxatridecanoil}ciclohexil] {2-O-benzoil-
                                             β-D-galactopiranosid-3-O-il})propanoico

                                             C58H74N6O31S3

                                                            O

                                                      HN           NH
                                                                             O
                                                  O                                          O

                                               H3C                  HN
                                                                                                 N
                                                            O                                    H
                                                                                                        HN     O
                                             HO                         O
                                                                                 O           O
                                                  HO            OH O                                           O

                                                                                         O
                                                          HO
                                                                                                                   O
                                                                   HO            O
                                                                                         CO2H
                                                                                                        HO3S       HN   O
                                                                                     H



                                                                                                 HO3S                   SO3H




                                                                                                                                    105
Recommended INN: List 71                                             WHO Drug Information, Vol. 28, No. 1, 2014


 roniciclibum
 roniciclib                    cyclopropyl(4-{[4-{[(2R,3R)-3-hydroxybutan-2-yl]oxy}-
                                                                                     5
                               5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)imino-λ -sulfanone

 roniciclib                    cyclopropyl(4-{[4-{[(2R,3R)-3-hydroxybutan-2-yl]oxy}-
                                                                                     5
                               5-(trifluorométhyl)pyrimidin-2-yl]amino}phényl)imino-λ -sulfanone

 roniciclib                    ciclopropil(4-{[4-{[(2R,3R)-3-hidroxibutan-2-il]oxi}-
                                                                                   5
                               5-(trifluorometil)pirimidin-2-il]amino}fenil)imino-λ -sulfanona

                               C18H21F3N4O3S

                                                                               O NH
                                         F3C                                    S
                                     H3C H                   N
                               H3C
                                               O         N       N
                                                                 H
                                    H OH

 ropeginterferonum alfa-2b #
 ropeginterferon alfa-2b       recombinant DNA derived human interferon alfa-2b with an added
                               pegylated proline at its N-terminal, produced in Escherichia coli
                               (nonglycosylated):
                               {1-[(3RS)-3,7-bis{[(ω-
                               methoxypoly(oxyethylene)carbonyl]amino}heptyl]-L-prolyl}human
                               interferon alpha-2B

 ropéginterféron alfa-2b       interféron alfa-2b humain auquel une proline pégylée a été rajoutée
                               du coté N-terminal, produit par Escherichia coli (non glycosylé) à
                               partir d'ADN recombinant :
                               {1-[(3RS)-3,7-bis{[(ω-
                               méthoxypoly(oxyéthylène)carbonyl]amino}heptyl]-L-prolyl}interféron
                               alpha-2B humain

 ropeginterferon alfa-2b       interferón alfa-2b humano con una prolina pegilada unida al extremo
                               N-terminal, producido por Escherichia coli (no glicosilado) a partir de
                               ADN recombinante :
                               {1-[(3RS)-3,7-bis{[(ω-metoxipoli(oxietilen)carbonil]amino}heptil]-
                               L-prolil}interferón alfa-2B humano

                               C876H1376N232O260S9[C2H4O]2n
                               Sequence / Séquence / Secuencia
                                                                                         P 0
                               CDLPQTHSLG      SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA 50
                               ETIPVLHEMI      QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI 100
                               QGVGVTETPL      MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS 150
                               FSLSTNLQES      LRSKE                                       165

                               Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                               1-98 29-138

                               Modified residue / Résidu modifié / Resto modificado                O
                                                                                                                  O
                                                                                      O
                                           P                                   H3C             O       NH        H C
                                                                                                   n
                                 1-[(mPEG)2link]Prolyl
                                                                                      HN                        N
                                                                           O
                                                                     H3C          O        O
                                                                                       n




106
WHO Drug Information, Vol. 28, No. 1, 2014                                                      Recommended INN: List 71


 sacubitrilum
 sacubitril                                  4-{[(2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-
                                             2-yl]amino}-4-oxobutanoic acid

 sacubitril                                  acide 4-{[(2S,4R)-1-([1,1'-biphényl]-4-yl)-5-éthoxy-4-méthyl-
                                             5-oxopentan-2-yl]amino}-4-oxobutanoïque

 sacubitrilo                                 ácido 4-{[(2S,4R)-1-([1,1'-bifenil]-4-il)-5-etoxi-4-metil-5-oxopentan-
                                             2-il]amino}-4-oxobutanoico

                                             C24H29NO5

                                                           O
                                                                           H
                                                                           N        CO2H
                                             H3C       O
                                                           H3C   H H           O




 sarecyclinum
 sarecycline                                 (4S,4aS,5aR,12aS)-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-
                                             7-{[methoxy(methyl)amino]methyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-
                                             octahydrotetracene-2-carboxamide

 sarécycline                                 (4S,4aS,5aR,12aS)-4-(diméthylamino)-3,10,12,12a-tétrahydroxy-
                                             7-{[méthoxy(méthyl)amino]méthyl}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-
                                             octahydrotétracène-2-carboxamide

 sareciclina                                 (4S,4aS,5aR,12aS)-4-(dimetilamino)-3,10,12,12a-tetrahidroxi-
                                             7-{[metoxi(metil)amino]metil}-1,11-dioxo-1,4,4a,5,5a,6,11,12a-
                                             octahidrotetraceno-2-carboxamida

                                             C24H29N3O8

                                                           OH    O         OH O     O
                                                                             OH
                                                                                          NH2

                                                                                     OH
                                                                       H       H
                                                   O                            H N CH3
                                             H3C       N
                                                                               H3C
                                                       CH3



 sarsageninum
 sarsagenin                                  (25S)-5β-spirostan-3β-ol

 sarsagénine                                 (25S)-5β-spirostan-3β-ol

 sarsagenina                                 (25S)-5β-espirostan-3β-ol




                                                                                                                      107
Recommended INN: List 71                                     WHO Drug Information, Vol. 28, No. 1, 2014


                           C27H44O3
                                                                         H
                                                              H              CH3
                                                      H3C         O
                                                      CH3
                                                              H
                                                                   O
                                         CH3      H
                                                                   H
                                             H        H
                           HO
                                H        H

 sisapronilum
 sisapronil                5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(1RS)-2,2-
                           difluoro-1-(trifluoromethyl)cyclopropyl]-1H-pyrazole-3-carbonitrile

 sisapronil                5-amino-1-[2,6-dichloro-4-(trifluorométhyl)phényl]-4-[(1RS)-2,2-
                           difluoro-1-(trifluorométhyl)cyclopropyl]-1H-pyrazole-3-carbonitrile

 sisapronilo               5-amino-1-[2,6-dicloro-4-(trifluorometil)fenil]-4-[(1RS)-2,2-difluoro-
                           1-(trifluorometil)ciclopropil]-1H-pirazol-3-carbonitrilo

                           C15H6Cl2F8N4

                                                  CN
                                                             CF3
                                    Cl       N                         and enantiomer
                                                                   F
                                             N                         et énantiomère
                                                                   F   y enantiómero
                                                  NH2
                           F3C               Cl

 smilageninum
 smilagenin                (25R)-5β-spirostan-3β-ol

 smilagénine               (25R)-5β-spirostan-3β-ol

 esmilagenina              (25R)-5β-espirostan-3β-ol

                           C27H44O3
                                                                         CH3
                                                              H            H
                                                      H3 C        O
                                                      CH3
                                                              H
                                                                   O
                                         CH3      H
                                                                   H
                                             H        H
                           HO
                                H        H

 tanurmotidum
 tanurmotide               human lymphocyte antigen 6K-(101-111)-peptide

 tanurmotide               antigène 6K lymphocytaire humain-(101-111)-peptide

 tanurmotida               antígeno 6K linfocitario humano-(101-111)-péptido

                           C51H80N14O15S

                           Sequence / Séquence / Secuencia
                           RYCNLEGPPI 10




108
WHO Drug Information, Vol. 28, No. 1, 2014                                                             Recommended INN: List 71




 tarextumabum #
 tarextumab                                  immunoglobulin G2-kappa, anti-[Homo sapiens NOTCH2 and
                                             NOTCH3], Homo sapiens monoclonal antibody;
                                             gamma2 heavy chain (1-441) [Homo sapiens VH (IGHV3-66*01
                                             (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) -
                                             IGHG2*01 (CH1 (116-213), hinge (214-225), CH2 (226-334), CH3
                                             (335-439), CHS (440-441)) (116-441)], (129-215')-disulfide with
                                             kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-20*02
                                             (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimer
                                             (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfide

 tarextumab                                  immunoglobuline G2-kappa, anti-[Homo sapiens NOTCH2 et
                                             NOTCH3], Homo sapiens anticorps monoclonal;
                                             chaîne lourde gamma2 (1-441) [Homo sapiens (IGHV3-66*01
                                             (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) -
                                             IGHG2*01 (CH1 (116-213), charnière (214-225), CH2 (226-334),
                                             CH3 (335-439), CHS (440-441)) (116-441)], (129-215')-disulfure
                                             avec la chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA
                                             (IGKV3-20*02 (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-
                                             215')]; dimère (217-217'':218-218'':221-221'':224-224'')-
                                             tétrakisdisulfure

 tarextumab                                  inmunoglobulina G2-kappa, anti-[NOTCH2 y NOTCH3 de Homo
                                             sapiens], anticuerpo monoclonal de Homo sapiens;
                                             cadena pesada gamma2 (1-441) [Homo sapiens (IGHV3-66*01
                                             (93.90%) -(IGHD)-IGHJ6*01 T123>L (110)) [8.8.8] (1-115) -
                                             IGHG2*01 (CH1 (116-213), bisagra (214-225), CH2 (226-334), CH3
                                             (335-439), CHS (440-441)) (116-441)], (129-215')-disulfuro con la
                                             cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-
                                             20*02 (94.40%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')];
                                             dímero (217-217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  SSGMSWVRQA       PGKGLEWVSV        50
                                             IASSGSNTYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCARSI       100
                                             FYTTWGQGTL VTVSSASTKG PSVFPLAPCS                  RSTSESTAAL       GCLVKDYFPE       150
                                             PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSN       FGTQTYTCNV       200
                                             DHKPSNTKVD KTVERKCCVE CPPCPAPPVA                  GPSVFLFPPK       PKDTLMISRT       250
                                             PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN                  AKTKPREEQF       NSTFRVVSVL       300
                                             TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI                  SKTKGQPREP       QVYTLPPSRE       350
                                             EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ                  PENNYKTTPP       MLDSDGSFFL       400
                                             YSKLTVDKSR WQQGNVFSCS VMHEALHNHY                  TQKSLSLSPG       K                441

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIVLTQSPAT LSLSPGERAT LSCRASQSVR                  SNYLAWYQQK       PGQAPRLLIY 50
                                             GASSRATGVP ARFSGSGSGT DFTLTISSLE                  PEDFAVYYCQ       QYSNFPITFG 100
                                             QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT                  ASVVCLLNNF       YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                  TLSKADYEKH       KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          142-198       255-315 361-419
                                                                    22''-96'' 142''-198'' 255''-315'' 361''-419''
                                             Intra-L (C23-C104) 23'-89'         135'-195'
                                                                   23'''-89''' 135'''-195'''
                                             Inter-H-L (CH1 10-CL 126) 129-215' 129''-215'''
                                             Inter-H-H (h 4, h 5, h 8, h 11) 217-217'' 218-218'' 221-221'' 224-224''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             291, 291''




                                                                                                                                          109
Recommended INN: List 71                                                                    WHO Drug Information, Vol. 28, No. 1, 2014




 taselisibum
 taselisib                                         2-methyl-2-(4-{2-[3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-
                                                   5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-1H-pyrazol-
                                                   1-yl)propanamide

 tasélisib                                         2-méthyl-2-(4-{2-[3-méthyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-
                                                   5,6-dihydroimidazo[1,2-d][1,4]benzoxazépin-9-yl}-1H-pyrazol-
                                                   1-yl)propanamide

 taselisib                                         2-metil-2-(4-{2-[3-metil-1-(propan-2-il)-1H-1,2,4-triazol-5-yl]-
                                                   5,6-dihidroimidazo[1,2-d][1,4]benzoxazepin-9-il}-1H-pirazol-
                                                   1-il)propanamida

                                                   C24H28N8O2


                                                                                    N        O
                                                   H3 C        N
                                                                                N                                   O
                                                           N       N                                                      NH2
                                                                           CH3
                                                                                                               N
                                                               H3C                                                      CH3
                                                                                                           N        CH3


             99m
 technetii ( Tc) trofolastati chloridum
             99m
 technetium ( Tc) trofolastat chloride             (OC-6-33)-tricarbonyl{(2S)-2-[({(1S)-1-carboxy-4-{[(1S)-1-carboxy-
                                                   5-(bis{[1-(2-{[bis(carboxymethyl)]amino}-2-oxoethyl)-1H-imidazol-
                                                           3
                                                   2-yl-κN ]methyl}amino-κN)pentyl]amino}-
                                                                                                   99m
                                                   4-oxobutyl]carbamoyl}amino)pentanedioic acid}( Tc)technetium
                                                   chloride
                               99m                                     99m
 chlorure de technétium (        Tc) trofolastat   chlorure de ( Tc)technétium acide (OC-6-33)-tricarbonyl{(2S)-2-
                                                   [({(1S)-1-carboxy-4-{[(1S)-1-carboxy-5-(bis{[1-(2-
                                                   {[bis(carboxyméthyl)]amino}-2-oxoéthyl)-1H-imidazol-
                                                           3
                                                   2-yl-κN ]méthyl}amino-κN)pentyl]amino}-
                                                   4-oxobutyl]carbamoyl}amino)pentanedioïque}
                         99m
 cloruro de tecnecio (     Tc) trofolastat         cloruro de ácido (OC-6-33)-tricarbonil{(2S)-2-[({(1S)-1-carboxi-
                                                   4-{[(1S)-1-carboxi-5-(bis{[1-(2-{[bis(carboximetil)]amino}-2-oxoetil)-
                                                                       3
                                                   1H-imidazol-2-il-κN ]metil}amino-κN)pentil]amino}-
                                                                                                 99m
                                                   4-oxobutil]carbamoil}amino)pentanedioico }( Tc)tecnecio

                                                   C40H50ClN10O23Tc

                                                                                                 CO2H

                                                                                            N
                                                    OC                         N
                                                               CO
                                                          99m Tc
                                                                       N                O        CO2H
                                                                                                                   Cl
                                                      OC
                                                               N           N                       CO2H

                                                           N                                    H NH
                                                                                            O                           CO2H
                                                                       O

                                                   HO2C            N           CO2H                H       O        H

                                                                                        HO2C           N           N      CO2H
                                                                                                       H           H




110
WHO Drug Information, Vol. 28, No. 1, 2014                                                               Recommended INN: List 71




 topsalysinum #
 topsalysin                                  recombinant DNA derived proaerolysin, pore-forming protein, from
                                             Aeromonas hydrophila, with the furin site substituted with a prostate
                                             specific antigen (PSA), fusion protein with 6 histidines, produced in
                                             Escherichia coli (nonglycosylated):
                                             [427-L-histidine(K>H),428-L-serine(V>S),429-L-serine(R>S),430-L-
                                             lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaerolysin
                                             Aeromonas hydrophila fusion protein with hexa-L-histidine

 topsalysine                                 proaérolysine, protéine formant des pores, d'Aeromonas hydrophila
                                             dont le site furine est substitué par un antigène prostatique
                                             spécifique, protéine de fusion avec 6 histidines, produit par
                                             Escherichia coli à partir d'ADN recombinant (non glycosylé) :
                                             [427-L-histidine(K>H),428-L-sérine(V>S),429-L-sérine(R>S),430-L-
                                             lysine(R>K),431-L-leucine(A>L),432-L-glutamine(R>Q)]proaérolysine
                                             d'Aeromonas hydrophila protéine de fusion avec l'hexa-L-histidine

 topsalisina                                 proaerolisina, proteína formadora de poros, d'Aeromonas hydrophila
                                             cuyo sitio furina está substituido por un antígeno prostático
                                             específico, proteína de fusión con 6 histidinas, producida por
                                             Escherichia coli a partir de ADN recombinante (no glicosilado) :
                                             [427-L-histidina(K>H),428-L-serina(V>S),429-L-serina (R>S),430-L-
                                             lisina(R>K),431-L-leucina(A>L),432-L-glutamina(R>Q)]proaerolisina
                                             d'Aeromonas hydrophila proteina de fusión con hexa-L-histidina
                                             Sequence / Séquence / Secuencia
                                             AEPVYPDQLR LFSLGQGVCG DKYRPVNREE                  AQSVKSNIVG       MMGQWQISGL       50
                                             ANGWVIMGPG YNGEIKPGTA SNTWCYPTNP                  VTGEIPTLSA       LDIPDGDEVD       100
                                             VQWRLVHDSA NFIKPTSYLA HYLGYAWVGG                  NHSQYVGEDM       DVTRDGDGWV       150
                                             IRGNNDGGCD GYRCGDKTAI KVSNFAYNLD                  PDSFKHGDVT       QSDRQLVKTV       200
                                             VGWAVNDSDT PQSGYDVTLR YDTATNWSKT                  NTYGLSEKVT       TKNKFKWPLV       250
                                             GETELSIEIA ANQSWASQNG GSTTTSLSQS                  VRPTVPARSK       IPVKIELYKA       300
                                             DISYPYEFKA DVSYDLTLSG FLRWGGNAWY                  THPDNRPNWN       HTFVIGPYKD       350
                                             KASSIRYQWD KRYIPGEVKW WDWNWTIQQN                  GLSTMQNNLA       RVLRPVRAGI       400
                                             TGDFSAESQF AGNIEIGAPV PLAADSHSSK                  LQSVDGAGQG       LRLEIPLDAQ       450
                                             ELSGLGFNNV SLSVTPAANQ HHHHHH                                                        476

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             19-75 159-164



 tosatoxumabum #
 tosatoxumab                                 immunoglobulin G1-lambda2, anti-[Staphylococcus aureus alpha-
                                             toxin (alpha-hemolysin, alpha-HL, hly, hla)], Homo sapiens
                                             monoclonal antibody;gamma1 heavy chain (1-451) [Homo sapiens
                                             VH (IGHV5-51*01 (81.60%) -(IGHD)-IGHJ1*01 L123>M (116))
                                             [8.8.14] (1-121) -IGHG1*01 (CH1 (122-219), hinge (220-234), CH2
                                             (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-
                                             disulfide with lambda light chain (1'-217') [Homo sapiens V-LAMBDA
                                             (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01
                                             (112'-217')]; dimer (230-230'':233-233'')-bisdisulfide

 tosatoxumab                                 immunoglobuline G1-lambda2, anti-[Staphylococcus aureus toxine
                                             alpha (hémolysine alpha, HL-alpha, hly, hla)], Homo sapiens
                                             anticorps monoclonal;
                                             chaîne lourde gamma1 (1-451) [Homo sapiens VH (IGHV5-51*01
                                             (81.60%) -(IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -
                                             IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344),
                                             CH3 (345-449), CHS (450-451)) (122-451)], (224-216')-disulfure
                                             avec la chaîne légère lambda (1'-217') [Homo sapiens V-LAMBDA
                                             (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -IGLC1*01
                                             (112'-217')]; dimère (230-230'':233-233'')-bisdisulfure




                                                                                                                                               111
Recommended INN: List 71                                     WHO Drug Information, Vol. 28, No. 1, 2014


 tosatoxumab               inmunoglobulina G1-lambda2, anti-[toxina alfa de Staphylococcus
                           aureus (hemolisina alfa, HL-alfa, hly, hla)], anticuerpo monoclonal de
                           Homo sapiens;
                           gamma1 (1-451) [Homo sapiens VH (IGHV5-51*01 (81.60%) -
                           (IGHD)-IGHJ1*01 L123>M (116)) [8.8.14] (1-121) -cadena pesada
                           (224-216')-disulfuro con la cadena ligera lambda (1'-217') [Homo
                           sapiens (IGLV1-44*01 (93.90%) -IGLJ1*01) [8.3.12] (1'-111') -
                           IGLC1*01 (112'-217')]; dímero (230-230'':233-233'')-bisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQMVQSGAE VKKPGEPLKI SCKGSGYKFG                  THWIGWVRQR       PGKGLEWMGI        50
                           IHPADSETKY SPSFQGQVSF SADKSSNTAY                  LHWSTLRASD       TAMYYCARRS       100
                           GSSSWYALDF WGQGTMVTVS SASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                           TYICNVNHKP SNTKVDKRVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                           PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                           NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                           QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                           VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                           K                                                                                   451

                           Light chain / Chaîne légère / Cadena ligera
                           QSVLTQSPSA SGTPGQRVTI SCSGGSSNIG                  SNTVNWYQQF       PGAAPKLLIY 50
                           TNNQRPSGVP DRFSGSKSGT SASLAISGLQ                  SEDEADYYCA       TWDDSLNGLY 100
                           VFGTGTKVTV LGQPKANPTV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                           VAWKADGSPV KAGVETTKPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                            217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H (C23-C104) 22-96          148-204       265-325   371-429
                                                 22''-96'' 148''-204'' 265''-325'' 371''-429''
                           Intra-L (C23-C104) 22'-89'         139'-198'
                                                 22'''-89''' 139'''-198'''
                           Inter-H-L (h 5-CL 126) 224-216' 224''-216'''
                           Inter-H-H (h 11, h 14) 230-230'' 233-233''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           301, 301''




 tovetumabum #
 tovetumab                 immunoglobulin G2-kappa, anti-[Homo sapiens PDGFRA (platelet-
                           derived growth factor receptor alpha subunit, PDGFR2, CD140a)],
                           Homo sapiens monoclonal antibody;
                           gamma2 heavy chain (1-446) [Homo sapiens VH (IGHV3-11*01
                           (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-
                           218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS (445-
                           446)) (121-446)], (134-215')-disulfide with kappa light chain (1'-215')
                           [Homo sapiens V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ5*01
                           I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dimer (222-
                           222'':223-223'':226-226'':229-229'')-tetrakisdisulfide

 tovétumab                 immunoglobuline G2-kappa, anti-[Homo sapiens PDGFRA (sous-
                           unité alpha du récepteur du facteur de croissance dérivé des
                           plaquettes, PDGFR2, CD140a)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma2 (1-446) [Homo sapiens VH (IGHV3-11*01
                           (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-
                           218), charnière (219-230), CH2 (231-339), CH3 (340-444), CHS
                           (445-446)) (121-446)], (134-215')-disulfure avec la chaîne légère
                           kappa (1'-215') [Homo sapiens V-KAPPA (IGKV1-39*01 (89.50%) -
                           IGKJ5*01 I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')];
                           dimère (222-222'':223-223'':226-226'':229-229'')-tétrakisdisulfure




112
WHO Drug Information, Vol. 28, No. 1, 2014                                                             Recommended INN: List 71


 tovetumab                                   inmunoglobulina G2-kappa, anti-[PDGFRA de Homo sapiens
                                             (subunidad alfa del receptor del factor de crecimiento derivado de
                                             las plaquetas, PDGFR2, CD140a)], anticuerpo monoclonal de Homo
                                             sapiens;
                                             cadena pesada gamma2 (1-446) [Homo sapiens VH (IGHV3-11*01
                                             (98.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1 (121-
                                             218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS (445-
                                             446)) (121-446)], (134-215')-disulfuro con la cadena ligera kappa (1'-
                                             215') [Homo sapiens V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ5*01
                                             I126>M (107)) [6.3.10] (1'-108') -IGKC*01 (109'-215')]; dímero (222-
                                             222'':223-223'':226-226'':229-229'')-tetrakisdisulfuro

                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             QVQLVESGGG LVKPGGSLRL SCAASGFTFS                   DYYMNWIRQA      PGKGLEWVSY        50
                                             ISSSGSIIYY ADSVKGRFTI SRDNAKNSLY                   LQMNSLRAED      TAVYYCAREG       100
                                             RIAARGMDVW GQGTTVTVSS ASTKGPSVFP                   LAPCSRSTSE      STAALGCLVK       150
                                             DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                   GLYSLSSVVT      VPSSNFGTQT       200
                                             YTCNVDHKPS NTKVDKTVER KCCVECPPCP                   APPVAGPSVF      LFPPKPKDTL       250
                                             MISRTPEVTC VVVDVSHEDP EVQFNWYVDG                   VEVHNAKTKP      REEQFNSTFR       300
                                             VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP                   IEKTISKTKG      QPREPQVYTL       350
                                             PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                   ESNGQPENNY      KTTPPMLDSD       400
                                             GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                   LHNHYTQKSL      SLSPGK           446

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIQMTQSPSS LSASVGDRVS ITCRPSQSFS                   RYINWYQQKP      GKAPKLLIHA 50
                                             ASSLVGGVPS RFSGSGSGTD FTLTISSLQP                   EDFATYYCQQ      TYSNPPITFG 100
                                             QGTRLEMKRT VAAPSVFIFP PSDEQLKSGT                   ASVVCLLNNF      YPREAKVQWK 150
                                             VDNALQSGNS QESVTEQDSK DSTYSLSSTL                   TLSKADYEKH      KVYACEVTHQ 200
                                             GLSSPVTKSF NRGEC                                                              215

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          147-203      260-320 366-424
                                                                    22''-96'' 147''-203'' 260''-320'' 366''-424''
                                             Intra-L (C23-C104) 23'-88'         135'-195'
                                                                    23'''-88''' 135'''-195'''
                                             Inter-H-L (CH1 10-CL 126) 134-215' 134''-215'''
                                             Inter-H-H (h 4, h 5, h 8, h 11) 222-222'' 223-223'' 226-226'' 229-229''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             296, 296''



 ubrogepantum
 ubrogepant                                  (3'S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-
                                             1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-
                                             1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-
                                             b]pyridine]-3-carboxamide

 ubrogépant                                  (3'S)-N-[(3S,5S,6R)-6-méthyl-2-oxo-5-phényl-
                                             1-(2,2,2-trifluoroéthyl)pipéridin-3-yl]-2'-oxo-
                                             1',2',5,7-tétrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-
                                             b]pyridine]-3-carboxamide

 ubrogepant                                  (3'S)-N-[(3S,5S,6R)-6-metil-2-oxo-5-fenil-
                                             1-(2,2,2-trifluoroetil)piperidin-3-il]-2'-oxo-
                                             1',2',5,7-tetrahidrospiro[ciclopenta[b]piridina-6,3'-pirrolo[2,3-
                                             b]piridina]-3-carboxamida

                                             C29H26F3N5O3

                                                                CF3
                                                        H
                                                H3C         N      O
                                                                       O
                                                    H
                                                                                                     N
                                                                  N
                                                                H H
                                                                                                  NH
                                                                                N
                                                                                            O



                                                                                                                                        113
Recommended INN: List 71                                  WHO Drug Information, Vol. 28, No. 1, 2014




 valbenazinum
 valbenazine               (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-
                           hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate

 valbénazine               L-valinate de (2R,3R,11bR)-9,10-diméthoxy-3-(2-méthylpropyl)-
                           1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoléin-2-yle

 valbenazina               L-valinato de (2R,3R,11bR)-9,10-dimetoxi-3-(2-metilpropil)-
                           1,3,4,6,7,11b-hexahidro-2H-pirido[2,1-a]isoquinolein-2-ylo

                           C24H38N2O4

                                        CH3   O

                               H3C                O
                                                      H
                                     H2 N H                     CH3
                                          H               H
                           H3CO                               CH3
                                                  N

                           H3CO


 vantictumabum #
 vantictumab               immunoglobulin G2-lambda, anti-[Homo sapiens frizzled family
                           receptor (FZD), including FZD1, FZD2, FZD5, FZD7 and FZD8)],
                           Homo sapiens monoclonal antibody;
                           gamma2 heavy chain (1-443) [Homo sapiens VH (IGHV3-23*04
                           (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) -
                           IGHG2*01 (CH1 (119-216), hinge (217-228), CH2 (229-337), CH3
                           (338-441), CHS (442-443)) (119-443)], (132-212')-disulfide with
                           lambda light chain (1'-213') [Homo sapiens V-LAMBDA (IGLV3-
                           25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01 (108'-213')];
                           dimer (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfide

 vantictumab               immunoglobuline G2-lambda, anti-[Homo sapiens récepteur de la
                           famille frizzled (FZD), incluant FZD1, FZD2, FZD5, FZD7 et FZD8)],
                           Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma2 (1-443) [Homo sapiens VH (IGHV3-23*04
                           (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) -
                           IGHG2*01 (CH1 (119-216), charnière (217-228), CH2 (229-337),
                           CH3 (338-441), CHS (442-443)) (119-443)], (132-212')-disulfure
                           avec la chaîne légère lambda (1'-213') [Homo sapiens V-LAMBDA
                           (IGLV3-25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01
                           (108'-213')]; dimère (220-220'':221-221'':224-224'':227-227'')-
                           tétrakisdisulfure

 vantictumab               inmunoglobulina G2-lambda, anti-[receptor de la familia frizzled
                           (FZD) de Homo sapiens, incluyendo FZD1, FZD2, FZD5, FZD7 et
                           FZD8)], anticuerpo monoclonal de Homo sapiens ;
                           cadena pesada gamma2 (1-443) [Homo sapiens VH (IGHV3-23*04
                           (90.80%) -(IGHD)-IGHJ6*01 T123>L (113)) [8.8.11] (1-118) -
                           IGHG2*01 (CH1 (119-216), bisagra (217-228), CH2 (229-337), CH3
                           (338-441), CHS (442-443)) (119-443)], (132-212')-disulfuro con la
                           cadena ligera lambda (1'-213') [Homo sapiens V-LAMBDA (IGLV3-
                           25*02 (81.60%) -IGLJ2*01) [6.3.10] (1'-107') -IGLC2*01 (108'-213')];
                           dímero (220-220'':221-221'':224-224'':227-227'')-tetrakisdisulfuro




114
WHO Drug Information, Vol. 28, No. 1, 2014                                                           Recommended INN: List 71



                                             Heavy chain / Chaîne lourde / Cadena pesada
                                             EVQLVESGGG LVQPGGSLRL SCAASGFTFS                  HYTLSWVRQA       PGKGLEWVSV        50
                                             ISGDGSYTYY ADSVKGRFTI SSDNSKNTLY                  LQMNSLRAED       TAVYYCARNF       100
                                             IKYVFANWGQ GTLVTVSSAS TKGPSVFPLA                  PCSRSTSEST       AALGCLVKDY       150
                                             FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSNFGTQTYT       200
                                             CNVDHKPSNT KVDKTVERKC CVECPPCPAP                  PVAGPSVFLF       PPKPKDTLMI       250
                                             SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE                  VHNAKTKPRE       EQFNSTFRVV       300
                                             SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE                  KTISKTKGQP       REPQVYTLPP       350
                                             SREEMTKNQV SLTCLVKGFY PSDIAVEWES                  NGQPENNYKT       TPPMLDSDGS       400
                                             FFLYSKLTVD KSRWQQGNVF SCSVMHEALH                  NHYTQKSLSL       SPG              443

                                             Light chain / Chaîne légère / Cadena ligera
                                             DIELTQPPSV SVAPGQTARI SCSGDNIGSF                  YVHWYQQKPG       QAPVLVIYDK 50
                                             SNRPSGIPER FSGSNSGNTA TLTISGTQAE                  DEADYYCQSY       ANTLSLVFGG 100
                                             GTKLTVLGQP KAAPSVTLFP PSSEELQANK                  ATLVCLISDF       YPGAVTVAWK 150
                                             ADSSPVKAGV ETTTPSKQSN NKYAASSYLS                  LTPEQWKSHR       SYSCQVTHEG 200
                                             STVEKTVAPT ECS                                                                213

                                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                             Intra-H (C23-C104) 22-96          145-201       258-318 364-422
                                                                    22''-96'' 145''-201'' 258''-318'' 364''-422''
                                             Intra-L (C23-C104) 22'-87' 135'-194'
                                                                   22'''-87''' 135'''-194'''
                                             Inter-H-L (CH1 10-CL 126) 132-212' 132''-212'''
                                             Inter-H-H (h 4, h 5, h 8, h 11) 220-220'' 221-221'' 224-224'' 227-227''

                                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                             H CH2 N84.4:
                                             294, 294''



 vatiquinonum
 vatiquinone                                 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-
                                             6,10,14-trien-1-yl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

 vatiquinone                                 2-[(3R,6E,10E)-3-hydroxy-3,7,11,15-tétraméthylhexadéca-
                                             6,10,14-trién-1-yl]-3,5,6-triméthylcyclohexa-2,5-diène-1,4-dione

 vatiquinona                                 2-[(3R,6E,10E]-3-hidroxi-3,7,11,15-tetrametilhexadeca-6,10,14-trien-
                                             1-il]-3,5,6-trimetilciclohexa-2,5-dieno-1,4-diona

                                             C29H44O3

                                                       O           HO CH3              CH3             CH3             CH3
                                             H3C
                                                                                                                          CH3

                                             H3C               CH3
                                                       O

 vedroprevirum
 vedroprevir                                 1-{[(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-bicyclo[3.1.0]hexan-
                                             3-yl]oxy}carbonyl)amino]-3,3-dimethylbutanoyl}-4-((8-chloro-
                                             7-[2-(morpholin-4-yl)ethoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-
                                             4-yl}quinolin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino}-
                                             2-ethylcyclopropane-1-carboxylic acid

 védroprévir                                 acide 1-{[(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-bicyclo[3.1.0]hexan-
                                             3-yl]oxy}carbonyl)amino]-3,3-diméthylbutanoyl}-4-((8-chloro-
                                             7-[2-(morpholin-4-yl)éthoxy]-2-{2-[(propan-2-yl)amino]-1,3-thiazol-
                                             4-yl}quinoléin-4-yl)oxy]pyrrolidin-2-yl]carbonylamino}-
                                             2-éthylcyclopropane-1-carboxylique

 vedroprevir                                 ácido 1-{[(2S,4R)-1-{(2S)-2-[({[(1R,3r,5S)-biciclo[3.1.0]hexan-
                                             3-il]oxi}carbonil)amino]-3,3-dimetilbutanoil}-4-((8-cloro-7-[2-(morfolin-
                                             4-il)etoxi]-2-{2-[(propan-2-il)amino]-1,3-tiazol-4-il}quinolin-
                                             4-il)oxi]pirrolidin-2-il]carbonilamino}-2-etilciclopropano-1-carboxílico




                                                                                                                                       115
Recommended INN: List 71                                        WHO Drug Information, Vol. 28, No. 1, 2014


                           C45H60ClN7O9S

                                                                                           S
                                                                Cl
                                                                                                  NH
                                                    O                        N
                                      N                                                    N           CH3
                                 O                                                             H3 C
                                                        CH3          H
                                              H3C
                                                         CH3                 O
                            H
                                          O
                                      H                     H
                                                                N                    H
                                      O        N                                     N     CO2H
                                               H
                            H                               O        H
                                                                             O                  CH3
                                                                                         H

 vericiguatum
 vericiguat                methyl [4,6-diamino-2-{5-fluoro-1-[(2-fluorophenyl)methyl]-
                           1H-pyrazolo[3,4-b]pyridin-3-yl}pyrimidin-5-yl]carbamate

 vériciguat                [4,6-diamino-2-{5-fluoro-1-[(2-fluorophényl)méthyl]-1H-pyrazolo[3,4-
                           b]pyridin-3-yl}pyrimidin-5-yl]carbamate de méthyle

 vericiguat                N-{4,6-diamino-2-[5-fluoro-1-[(2-fluorofenil)metil]-1H-pirazolo[3,4-b]-
                           piridin-3-il]pirimidin-5-il}carbamato de metilo

                           C19H16F2N8O2

                                                        NH2
                                                                    H
                                                                    N            O
                                                    N                                CH3
                                          N                              O
                           F                            N           NH2
                                      N


                                      N

                                                    F

 vilaprisanum
 vilaprisan                20,20,21,21,21-pentafluoro-17-hydroxy-
                           11β-[4-(methanesulfonyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one

 vilaprisan                20,20,21,21,21-pentafluoro-17-hydroxy-
                           11β-[4-(méthanesulfonyl)phényl]-19-nor-17α-prégna-4,9-dién-3-one

 vilaprisán                20,20,21,21,21-pentafluoro-17-hidroxi-11β-[4-(metanosulfonil)fenil]-
                           19-nor-17α-pregna-4,9-dien-3-ona

                           C27H29F5O4S

                                O O
                                 S
                           H3C
                                                H           CH3 OH CF3

                                                                                 F
                                                        H                F

                                                            H
                                 O




116
WHO Drug Information, Vol. 28, No. 1, 2014                                                      Recommended INN: List 71


 voruciclibum
 voruciclib                                         2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-
                                                    8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-
                                                    4H-1-benzopyran-4-one

 voruciclib                                         2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-
                                                    8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-
                                                    4H-1-benzopyran-4-one

 voruciclib                                         2-[2-cloro-4-(trifluorometil)fenil]-5,7-dihidroxi-
                                                    8-[(2R,3S)-2-(hidroximetil)-1-metilpirrolidin-3-il]-4H-1-benzopiran-
                                                    4-ona

                                                    C22H19ClF3NO5

                                                         CH3
                                                         N            OH
                                                                  H       Cl     CF3
                                                                  H
                                                    HO                O




                                                             OH       O




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf

                                                                                                                           117
Recommended INN: List 71                                            WHO Drug Information, Vol. 28, No. 1, 2014




                             AMENDMENTS TO PREVIOUS LISTS
                     MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                         MODIFICACIONES A LAS LISTAS ANTERIORES
 
 
Recommended International Nonproprietary Names (Rec. INN): List 1
(Chron. Wld Hlth Org., Vol. 9, No 6, 1955)
 
p. 190    delete                       insert
          methacholinii chloridum      methacholini chloridum
          methacholinium chloride      methacholine chloride
 
 
Dénominations communes internationales recommandées (DCI rec.): Liste 1
(Chron. Org. mond. Santé, Vol. 9, No 6, 1955)
 
p. 206    supprimer                    insérer
          methacholinii chloridum      methacholini chloridum
          chlorure de méthacholinium   chlorure de méthacholine
 
 
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 1
(Crón. Org. mund. Salud, Vol. 9, No 6, 1955)
 
p. 209    suprimáse                    insertese
          methacholinii chloridum      methacholini chloridum
          cloruro de metacolinio       cloruro de metacolina
 
 
Recommended International Nonproprietary Names (Rec. INN): List 3
(Chron. Wld Hlth Org., Vol. 13, No. 12, 1959)
 
p. 463    delete                        insert
          acetylcholinii chloridum      acetylcholini chloridum
 
p. 465    delete                        insert
          cholinii chloridum            cholini chloridum
 
p. 470    delete                        insert
          nitricholinii perchloras      nitricholini perchloras
          nitricholinium perchlorate    nitricholine perchlorate
 
 
Dénominations communes internationales recommandées (DCI rec.): Liste 3
(Chron. Org. mond. Santé, Vol. 13, No. 12, 1959)
 
p. 482    supprimer                     insérer
          acetylcholinii chloridum      acetylcholini chloridum
 

118
WHO Drug Information, Vol. 28, No. 1, 2014                                Recommended INN: List 71



 
 
p. 484    supprimer                       insérer
          cholinii chloridum              cholini chloridum
 
p. 489    supprimer                       insérer
          nitricholinii perchloras        nitricholini perchloras
          perchlorate de nitricholinium   perchlorate de nitricholine
 
 
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 3
(Crón. Org. mund. Salud, Vol. 13, No. 12, 1959)
 
p. 496    suprimáse                       insertese
          acetylcholinii chloridum        acetylcholini chloridum
 
p. 498    suprimáse                       insertese
          cholinii chloridum              cholini chloridum
 
p. 503    suprimáse                       insertese
          nitricholinii perchloras        nitricholini perchloras
          perclorato de nitricolinio      perclorato de nitrocolina
 
 
Recommended International Nonproprietary Names (Rec. INN): List 4
(Chron. Wld Hlth Org., Vol. 16, No. 3, 1962)
 
p. 103    delete                          insert
          cholinii gluconas               cholini gluconas
          cholinium gluconate             choline gluconate
 
 
Dénominations communes internationales recommandées (DCI rec.): Liste 4
(Chron. Org. mond. Santé, Vol. 16, No. 3, 1962)
 
p. 114    supprimer                       insérer
          cholinii gluconas               cholini gluconas
          gluconate de cholinium          gluconate de choline
 
 
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 4
(Crón. Org. mund. Salud, Vol. 16, No. 3, 1962)
 
p. 154    suprimáse                       insertese
          cholinii gluconas               cholini gluconas
          gluconato de colinio            gluconato de colina
 




                                                                                               119
Recommended INN: List 71                                                       WHO Drug Information, Vol. 28, No. 1, 2014


Recommended International Nonproprietary Names (Rec. INN): List 62
Dénominations communes internationales recommandées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 258 &   ramucirumabum #
259        ramucirumab               replace the description and the structure by the following ones
           ramucirumab               remplacer la description et la structure par les suivantes
           ramucirumab               sustitúyase la descripción y la estructura por los siguientes

                                     immunoglobulin G1-kappa, anti-[Homo sapiens KDR (kinase insert domain receptor,
                                     vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)
                                     extracellular domain], Homo sapiens monoclonal antibody;
                                     gamma1 heavy chain (1-446) [Homo sapiens VH (IGHV3-21*01(99.00%) -(IGHD)-
                                     IGHJ3*02) [8.8.9] (1-116) - IGHG1*03 (CH1 F5>L (125), hinge (215-229), CH2 (230-
                                     339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa
                                     light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -IGKJ4*01
                                     E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimer (225-225'':228-228'')-
                                     bisdisulfide

                                     immunoglobuline G1-kappa, anti-[Homo sapiens KDR (récepteur à domaine insert
                                     kinase, récepteur 2 du facteur de croissance endothélial vasculaire, VEGFR2,
                                     VEGF-R2, FLK1, CD309) domaine extracellulaire], Homo sapiens anticorps
                                     monoclonal;
                                     chaîne lourde gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01 (99.00%) -(IGHD)-
                                     IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), charnière (215-229), CH2
                                     (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la
                                     chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -
                                     IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-
                                     225'':228-228'')-bisdisulfure

                                    inmunoglobulina G1-kappa, anti-[Homo sapiens KDR (receptor con dominio insert-
                                    kinasa, receptor 2 del factor de crecimiento endotelial vascular, VEGFR2, VEGF-R2,
                                    FLK1, CD309) dominio extracelular], Homo sapiens anticuerpo monoclonal;
                                    cadena pesada gamma1 (1-446) [Homo sapiens VH (IGHV3-21*01 (99.00%) -
                                    (IGHD)-IGHJ3*02) [8.8.9] (1-116) -IGHG1*03 (CH1 F5>L (125), bisagra (215-229),
                                    CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con
                                    la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-12*01 (85.30%) -
                                    IGKJ4*01 E125>D (105)) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-
                                    225'':228-228'')-bisdisulfuro
                                    Error! Objects cannot be created from editing field codes.
Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)
 
p. 91    upamostatum                 
         upamostat                  replace the chemical name by the following one
         upamostat                  remplacer le nom chimique par le suivant
         upamostat                  sustitúyase el nombre químico por el siguiente
                                     ethyl 4-{(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phenyl}-
                                     2-[2,4,6-tri(propan-2-yl)benzenesulfonamido]propanoyl}piperazine-
                                     1-carboxylate}

                                     4-{(2S)-3-{3-[(E)-N'-hydroxycarbamimidoyl]phényl}-
                                     2-[2,4,6-tri(propan-2-yl)benzènesulfonamido]propanoyl}pipérazine-
                                     1-carboxylate d'éthyle

                                     4-{(2S)-3-{3-[(E)-N’-hidroxicarbamimidoil]fenil}-2-[2,4,6-tri(propan-
                                     2-il)bencenosulfonamido]propanoil}piperazina-1-carboxilato de etilo
 
Recommended International Nonproprietary Names (Rec. INN): List 69


120
WHO Drug Information, Vol. 28, No. 1, 2014                                                        Recommended INN: List 71


Dénominations communes internationales recommandées (DCI Rec.): Liste 69
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69
(WHO Drug Information, Vol. 27, No. 1, 2013)
 
p. 82    tenapanorum                 
         tenapanor                  replace the chemical name by the following one
         ténapanor                  remplacer le nom chimique par le suivant
         tenapanor                  sustitúyase el nombre químico por el siguiente
                                     N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-
                                     1,26-diyl)bis{3-[(4S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-
                                     4-yl]benzenesulfonamide}

                                     N,N'-(10,17-dioxo-3,6,21,24-tétraoxa-9,11,16,18-tétraazahexacosane-
                                     1,26-diyl)bis{3-[(4S)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin-
                                     4-yl]benzènesulfonamide}

                                     N,N'-(10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano-
                                     1,26-diyl)bis{3-[(4S)-6,8-dicloro-2-metil-1,2,3,4-tetrahidroisoquinolin-
                                     4-il]bencenosulfonamida}
 
Recommended International Nonproprietary Names (Rec. INN): List 70
Dénominations communes internationales recommandées (DCI Rec.): Liste 70
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 70
(WHO Drug Information, Vol. 27, No. 3, 2013)
 
p. 306  polatuzumabum vedotinum #
& 307   polatuzumab vedotin       replace the description by the following one
        polatuzumab védotine      remplacer la description par la suivante
        polatuzumab vedotina      sustitúyase la descripción por la siguiente
                                    immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens CD79B
                                    (immunoglobulin-associated CD79 beta)], humanized monoclonal antibody conjugated to
                                    auristatin E;
                                    gamma1 heavy chain (1-447) [humanized VH (Homo sapiens IGHV3-23*04 (76.50%) -
                                    (IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 R120>K (214) (118-
                                    215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-
                                    218')-disulfide with kappa light chain (1’-218’) [humanized V-KAPPA (Homo sapiens
                                    IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (112'-218')];
                                    dimer (226-226":229-229")-bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to
                                    monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-
                                    p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker
                                    For the vedotin part, please refer to the document “INN for pharmaceutical substances:
                                    Names for radicals, groups and others”*.
                                    immunoglobuline G1-kappa conjuguée à l’auristatine E, anti-[Homo sapiens CD79B
                                    (CD79 bêta associé à l’immunoglobuline)], anticorps monoclonal humanisé conjugué
                                    à l’auristatine E;
                                    chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens IGHV3-23*04 (76.50%)
                                    -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1 R120>K (214)
                                    (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447))
                                    (118-447)], (220-218')-disulfure avec la chaîne légère kappa (1’-218’) [V-KAPPA
                                    humanisé (Homo sapiens IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-111') -Homo
                                    sapiens IGKC*01 (112'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur
                                    3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker
                                    clivable de type maléimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-
                                    cit-PABC)
                                    Pour la partie védotine, veuillez vous référer au document “INN for pharmaceutical
                                    substances: Names for radicals, groups and others”*.

                                    inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo sapiens CD79B
                                    (CD79 beta associado a la inmunoglobulina)], anticuerpo monoclonal humanizado
                                    conjugado con auristatina E;
                                    cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens IGHV3-23*04
                                    (76.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (CH1
                                    R120>K (214) (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS

                                                                                                                           121
 Recommended INN: List 71                                                          WHO Drug Information, Vol. 28, No. 1, 2014


                                    (446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera kappa (1’-218’) [V-
                                    KAPPA humanizado (Homo sapiens IGKV1-39*01 (85.90%) -IGKJ1*01) [10.3.9] (1'-
                                    111') -Homo sapiens IGKC*01 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro;
                                    conjuguado, en 3 a 4 restos cisteinil por término medio, con monometilauristatina E
                                    (MMAE), mediante un vínculo escindible maleimidocaproil-valil-citrullinil-
                                    p-aminobenziloxicarbonil (mc-val-cit-PABC)
                                    Para la fracción vedotina se pueden referir al documento "INN for pharmaceutical
                                    substances: Names for radicals, groups and others"*.
  
 p. 313    sofosbuvirum
           sofosbuvir              replace the structure by the following one
           sofosbuvir              remplacer la structure par la suivante
           sofosbuvir              sustitúyase la estructura por la siguiente



                                                                                   H
                                                                         O         N    O
                                               H 3C   H O O
                                   H3C     O             P           O       N
                                                       N   O
                                                       H
                                         CH3    O
                                                                             CH3
                                                                HO       F




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




 122
